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 ABSTRACT 
 
In the United States, as of 2016 there were around 28 million individuals with 
chronic non-cancer pain (CNCP) conditions. If uncontrolled, CNCP can have enormous 
economic, societal and health consequences. Currently, a common treatment for CNCP 
is long-term opioid therapy. If used properly, opioid treatment can relieve pain and 
increase quality of life with manageable adverse effects. However, opioid treatment is 
controversial due to the health and economic burden from the potential for addiction and 
other serious adverse effects, and from the prevalence of diversion of opioids to non-
therapeutic uses. This retrospective study estimates the impact of pain management with 
and without opioids on medical expenditures for CNCP conditions. The data sources are 
12-years Medical Expenditure Panel Survey (MEPS) data and 5-years commercial 
claims data from Blue Cross Blue Shield of Texas (BCBSTX). Two analytic approaches 
were applied to both data sets: 1) cross-sectional descriptive analysis and regression 
models to evaluate differences in service utilization and expenditure among CNCP 
patients with and without opioid treatment; and 2) longitudinal analysis to examine 
changes in health outcomes and expenditures for before and after new episodes of opioid 
treatment for CNCP patients.  Results from analyses of both datasets indicated higher 
CNCP treatment costs associated with opioid treatment. 
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CHAPTER 1. INTRODUCTION  
 
According to a well-cited report from the Institute of Medicine (IOM) “Relieving 
Pain in America: A Blueprint for Transforming Prevention, Care, Education, and 
Research,” there are 100 million Americans suffering from chronic pain (IOM, 2011; 
Simon, 2012), with an associated cost of $560 to $635 billion annually in lost 
productivity and medical care (Gaskin & Richard, 2012). Among all chronic pain 
patients, there were around 28 million individuals with chronic non-cancer pain (CNCP) 
conditions (Chou, Fanciullo, Fine, Adler, et al., 2009).  
If uncontrolled, CNCP can have enormous economic, societal and health 
consequences. A 2015 study estimated the annual consumption of healthcare resources 
among patients suffering from CNCP are nearly twice the level of the consumption of 
healthcare resources in the general population (Henschke, Kamper, & Maher, 2015). 
Currently, a common treatment for CNCP is long-term opioid therapy, which is 
controversial due to the need to balance the benefits to patients of more effective pain 
management with the risk for addiction and abuse.  
From 2000 to 2010, the prevalence of individuals diagnosed with conditions 
indicative of chronic pain has been consistent, but over the same period the rate of 
opioid prescriptions among patients with chronic pain conditions almost doubled, from 
11.3% to 19.6% (Daubresse et al., 2013).  Although by 2017 the volume of total opioid 
prescriptions had declined 29% from the peak volume in 2011 (IQVIA, 2018), American 
Society of Addiction Medicine estimated 20,101 overdose deaths related to prescription 
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pain relievers in 2016. (American Society of Addiction Medicine, 2016). On October 
27th, 2017, the Trump administration declared the opioid crisis a public health 
emergency.  
Many previous studies have investigated CNCP and opioid use from different 
perspectives to investigate the medical and social impact of CNCP conditions, and the 
cost and outcomes of opioid treatment on CNCP population (Campbell et al., 2015; 
Henschke et al., 2015; Kern et al., 2015; Vowles et al., 2015). Some studies estimated 
the economic burden of opioid treatment by secondary data analysis or clinical trials, 
and tried to prove higher healthcare utilization for long term opioid treatment to CNCP 
(Kirson et al., 2017; Kay, Wozniak, & Bernstein, 2017; Scarpati, Kirson, Jia, Wen, & 
Howard, 2017).  
Still, little had been known about the impact of opioid treatment on healthcare 
costs for CNCP patients overtime, and the specific treatments constituting the major 
drivers of cost differences. Other longitudinal studies have described the pattern of 
healthcare utilization and cost over a long term (more than 1 year) adjusted for patients’ 
characteristics, treatment pattern, and other related factors (Kern et al., 2015; Maeng, 
Han, Fitzpatrick, & Boscarino, 2017). But the studies were based on claims data from a 
solo healthcare system, lacking the generalization to represent the national scale, not to 
mention these two studies included all types of chronic patients and did not focus on 
CNCP patients. 
The objective of this study is to estimate medical expenditures and utilization 
patterns for CNCP patients using a longitudinal national sample obtained from several 
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years of Medical Expenditure Panel Survey (MEPS) data and replicate the MEPS results 
using commercial claims data from Blue Cross Blue Shield of Texas (BCBSTX). The 
specific aims of the study include: 1) cross-sectional analysis to estimate annual total 
medical expenditure for CNCP patients with and without opioid treatment, and 2) 
longitudinal analysis to estimate the difference in medical expenditure for CNCP 
patients initiation or not new opioid treatment episode.  
 
1.1 Literature Review  
In this section, I reported the results of a comprehensive literature review to 
explore the definition, pathogenesis, effectiveness of treatments, and economic impact of 
CNCP and opioid treatment for CNCP patients. The review was divided into three parts: 
1) Definition, Prevalence, and Management for CNCP; 2) Effectiveness and Side-effects 
of Opioid Treatments for CNCP; and 3) Medical Expenditures and Economics Burden of 
Opioid Treatment for CNCP. 
1.1.1 Definition, Prevalence, and Management for CNCP 
The International Association for the Study of Pain (IASP) defined pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage” (IASP, 1994). The American Pain 
Society defined chronic or long-term pain as pain sustained more than six months, which 
disturbs numerous lives all over the world across different ages and genders (The 
American Pain Society, 2000).   
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Due to the variances of pathophysiological mechanisms, chronic pain often was 
classified as chronic cancer pain or chronic non-cancer pain (CNCP) (Dennis C. Turk & 
Okifuji, 1998). The term chronic non-cancer pain (CNCP) relates to many kinds of 
conditions, including musculoskeletal pain, neuropathic pain, fibromyalgia, osteoarthritis 
and rheumatoid arthritis, but excluding headache, migraine, angina pectoris, cancer pain 
and pain associated with specific disease conditions (e.g. multiple sclerosis) (Reid, et al., 
2011).  
In the United States, the Institute of Medicine estimated that there were around 
116 million Americans with chronic pain conditions (Committee on Advancing Pain 
Research Care & Institute of Medicine, 2011), of which 78% are CNCP (Croft, 2010). A 
more conservative estimate by the Mayday Fund assessed the prevalence of chronic pain 
is 70 million Americans (Mayday Fund, 2009). In 15 European countries and Israel, one 
large-scale computer-assisted telephone survey revealed that 19% of the participants had 
suffered chronic pain, 34% of those affected by chronic pain had severe pain and 60% 
visited their doctor due to their pain 2-9 times during the last six months (Breivik, 
Collett, Ventafridda, Cohen, & Gallacher, 2006).  
According to the American Pain Society, in 2010, 25% of the adult population 
had moderate to severe CNCP, which was disabling for 10% of the population (Croft, 
2010), and 6% of the adult population have had pain for more than 5 years, which 
significantly reduced their quality of life (The American Pain Society, 2000).   
According to the IOM, the prevalence of CNCP was expected to continue to 
grow (Institute of Medicine, 2011). Several factors contributed to this expected growth. 
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Lifespans for general population had been increasing, and the baby-boom generation had 
been getting older. Population aging was increasing the prevalence of chronic conditions 
associated with chronic pain (Lipton, 2011). Moreover, advances in trauma medicine 
had reduced the rate of mortality from severe traumatic accidents, but survivors often 
have chronic pain conditions. Also, the obesity epidemic was becoming a serious health 
and social problem in the United States. Studies indicated that obesity increased the risk 
of chronic pain through a pro-inflammatory condition, which contributed to the growth 
in aggregate CNCP prevalence (McCarthy, Bigal, Katz, Derby, & Lipton, 2009).  
CNCP is not only one of the most prevalent reasons for doctor visits, but also 
reduces people’s quality of life (Gureje, Von Korff, Simon, & Gater, 1998). The 
Collaborative Study of Psychological Problems in General Health Care, which was 
conducted by the World Health Organization (WHO), predicted that 22% of primary 
care patients had pain persisting more than five months that restricted their daily 
activities and requires medical care (Gureje et al., 1998; Sullivan et al., 2008). 
Undoubtedly, CNCP conditions are serious health problems with heavy cost 
implications. One study estimated the general economic costs for CNCP was around 
$560 to $635 billion per year (in 2010-dollars) (Gaskin & Richard, 2012). 
If not managed properly, CNCP could cause complicated and serious health 
outcomes for patients. It interferes with patients’ daily activities, disrupts sleep, 
decreases the productivity for their work, affects mood and might cause mental health 
problems. The risk of suicide for CNCP patients was almost twice the risk for 
individuals without chronic pain (Chapman, 2013). 
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The growth in the prevalence of CNCP, often coupled with the inadequate 
management of chronic pain, creating a dilemma for opioid treatment. Since cancer pain 
is predominantly somatogenic, the prevailing treatments for cancer pain are “with 
pharmacological, medical, or surgical modalities” (Dennis C. Turk et al., 1998). To be 
more specific, the treatments could include epidural, intrathecal anaesthetic or spinal 
anaesthetic, as well as coeliac plexus, splanchnicectomy or thoracoscopic 
sympathectomy (nerve block), plus electrical nerve stimulation (TENS) and acupuncture 
and so on (National Institute on Drug Abuse, 2018).  
Otherwise, in the absence of adequate objective physical pathology and limited 
understandings of nociceptive or neuropathic nature (Dennis C. Turk et al., 1998), some 
CNCP conditions had been caused, increased, or prolonged by mental, emotional, or 
behavioral factors (Lian, Shah, Mueller, & Welliver, 2017), such as headache, back pain, 
or stomach pain (Cheng, 2018). These sources of pain often are regarded as psychogenic 
pain with no objectively observed cause, but in most cases CNCP is associated with 
organic processes that exacerbate pain noticeably (Chandler, Dinterstein, 
Haythornthwaite, & Wager, 2015). The treatment for psychogenic pain is harder than 
nociceptive pain or neuropathic pain, since the traditional treatments are designed for 
inflammation or nerve dysfunction conditions (Portenoy et al., 2007). Opioid treatment 
is especially inappropriate for psychogenic pain (A. Rosenblum, Marsch, Joseph, & 
Portenoy, 2008). 
Past studies suggest CNCP were managed most effectively using a 
multidisciplinary approach, which included psychological interventions, physical 
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therapies, and nutrition treatment (Jeffery, Butler, Stark, & Kane, 2011; Scascighini, 
Toma, Dober-Spielmann, & Sprott, 2008, Dennis C. Turk, Wilson, & Cahana, 2013; 
Health Quality, 2016; Perry, VanDenKerkhof, Wilson, & Tripp, 2017). However, 
various reasons made multidisciplinary treatment less appealing in reality, such as lack 
of certified pain specialists, physicians who are not well-prepared to manage CNCP, and 
difficulty in coordinating the multidisciplinary treatment by different providers, as well 
as resistance from payers (Chapman, 2013; Perry et al., 2017). Though its long-term 
efficacy has been questioned (Rosenblum et al., 2003), opioids are commonly used as a 
long-term treatment for CNCP. Opioids work by exerting their activity on opioid 
receptors, and have been considered as “the most potent analgesics for the treatment of 
severe acute, surgical and cancer pain” (Furlan, Sandoval, Mailis-Gagnon, & Tunks, 
2006; Heit, 2001). Boudreau et al. (Boudreau et al., 2009) estimate that more than 3% of 
adults with CNCP condition received chronic opioid therapy.  
In the last twenty years, there has been a growing trend of using opioid 
treatments for CNCP. Although opioids treatments have been used for acute pain for a 
long time, the cost-effectiveness of opioids for CNCP is still controversial. Before the 
1990s, opioids were mainly used for patients with advanced cancer. However, in 1986, a 
retrospective study of 38 CNCP patients with long-term opioid treatment showed 
success of pain relief without significant adverse effect (Portenoy & Foley, 1986).  
Followed by many studies with similarly positive results, Portenoy and Foley’s study 
changed the landscape of the CNCP treatment.  
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The pharmaceutical industry seized this chance to develop new opioid drugs and 
to market them aggressively by developing patient advocacy and physician education 
programs. The new drug got FDA approval during 90s included Duragesic in 1990, 
OxyContin in 1995, and Actiq (fentanyl) in 1998 (FDA, 2018). OxyContin is the first 
formulation of oxycodone which can be dosed every 12 hours rather than 4 to 6 hours 
and the controlled-release capsule design caused unexpected high level of abuse by oral 
ingestion or snorting. Back to then, FDA believed the controlled-release formulation of 
OxyContin could reduce potential abuse due to the slow absorbing of the drug to avoid 
the immediate high that causes abuse. In 1997, a consensus statement was published 
jointly by the American Pain Society and the American Academy of Pain Medicine 
provided guidelines which endorsed the use of opioid treatment for CNCP. The 
guideline said, “Opioid are an essential part of a pain management part” (American 
Academy of Pain Medicine & American Pain Society, 1997).  
From 2000 to 2010, the diagnosis of primary symptoms of pain has been 
consistent, but opioid prescriptions increased almost two-fold from 11.3% to 19.6% 
(Daubresse et al., 2013). While by 2017 the volume of total opioid prescriptions had 
declined 29% from the peak volume in 2011 (IQVIA, 2018), the Center for Behavior 
Health Statistics and Quality estimated there 10,635,000 adults that misused pain 
relievers in year 2016 (Substance Abuse and Mental Health Services Administration, 
2017). Coupled with the increase of consumption of opioids for CNCP, the painkiller 
overdoses related emergency department visits and mortality ratio have increased 
(Braden, Russo, Fan, & et al., 2010; Dart et al., 2015). American Society of Addiction 
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Medicine estimates 20,101 overdose deaths related to prescription pain relievers in 2016 
(American Society of Addiction Medicine, 2016).   
1.1.2 Effectiveness and adverse-effects of opioid treatments 
The major concerns about long-term opioid treatment for CNCP include the 
unclear effectiveness and adverse-effects of opioids, the physical tolerance due to usage 
of opioids, addiction and abuse of opioids (Furlan et al., 2006). Some researchers argued 
that although the usage and abuse of therapeutic opioids increased dramatically during 
the past 15 to 20 years, there still is not clear evidence for “the effectiveness of opioids 
for chronic non-cancer pain” (Manchikanti, Fellows, & Ailinani, 2010).  Other studies 
also conclude that strong evidence supporting the effectiveness of opioids for the 
treatment of CNCP is lacking (Chou, Fanciullo, Fine, Miaskowski, et al., 2009; 
Manchikanti et al., 2010; Manchikanti & Singh, 2008; Trescot et al., 2008).  
Beyond concerns about the efficacy for therapeutic opioids usage for CNCP, 
other studies have raised concerns about various adverse effects of opioid treatment.  
These included “problematic physiologic effects” such as “hyperalgesia (Abs et al., 
2000), hypogonadism and sexual dysfunction” (Angst & Clark, 2006), and adverse side 
effects that the potential for misuse and abuse and the increase in opioid-related deaths 
(Robinson et al., 2001). In a serial cross-sectional analysis, Gomes et al found that the 
percentage of all deaths attributable to opioids increased 292% (from 0.4% to 1.5%) 
between 2001 and 2016, resulting in approximately 1.68 million person-years of life lost 
in 2016 alone (5.2 per 1000 population). The burden was particularly high among adults 
aged 24 to 35 years; in 2016, 20% of deaths in this age group involved opioids (Gomes, 
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Tadrous, Mamdani, Paterson, & Juurlink, 2018). Some studies tried to investigate the 
factors contributing to increase of opioid prescription and the correlation ship to the 
overdose death. Hadland et al. found marketing of opioid products to physicians was 
associated with increased opioid prescribing and, subsequently, with raised mortality 
from overdoses. Addressing a national opioid overdose crisis, it is necessary to explore 
the influence of the pharmaceutical industry (Hadland, Rivera-Aguirre, Marshall, & 
Cerdá, 2019). 
In order to fully evaluate the impact of opioid treatment, Manchikanti and his 
colleagues conducted a comprehensive review of literature on the effectiveness of long-
term opioid therapy for CNCP. Their primary outcome measure was pain relief and sub-
outcome variables included functional improvement and adverse effects (Laxmaiah 
Manchikanti & Vallejo, 2011). They found that only one specific drug of opioid, 
tramadol, showed effectiveness of pain relief and improvement of functional status. Due 
to lack of evidence of effectiveness of long-term opioid therapy for CNCP from the 
comprehensive review, they claimed more restraint and caution for opioid usage 
(Laxmaiah Manchikanti & Vallejo, 2011).   
Kissin (2013) conducted a scientometic analysis, which was the science of 
measuring the impact of scientific publications (Harnad, 2009) testing the efficacy of 
long-term opioid treatment of chronic nonmalignant pain. This study did not discover 
any randomized controlled trial having opioid treatment for more than three months. 
Some trials had long-term (longer than 6 months) opioid treatment, but none of them had 
a control group (Kissin, 2013). This paper reflected the truth of missing consistent high-
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quality evidence to support clinical recommendation of long-term opioid treatment 
(Kissin, 2013).    
A more recent systematic review for the effectiveness and risk of long-term 
opioid therapy for chronic pain found there were no previous studies comparing long-
term outcomes of opioid therapy compared to no opioid therapy (Chou et al., 2015).  
They found there were associations between opioid therapy for chronic pain and the 
higher chance of overdose, opioid abuse, fractures and some other side effects (Chou et 
al., 2015). They concluded that there was insufficient evidence to support the 
effectiveness of long-term opioid treatment for improving chronic pain and function, and 
limited evidence for association between different doses of opioids. They also 
investigated the harms related of opioid therapy for chronic pain. They found evidence 
to show that opioid therapy for chronic pain increased risk for opioid abuse and 
overdose, fractures, myocardial infarction and utilization of sexual dysfunction 
medications (Chou et al., 2015). Another review article summarized the existing basic 
and clinical studies of opioid-induced hyperalgesia (OIH), which is a state of nociceptive 
sensitization triggered by exposure to opioids (Lee, Silverman, Hansen, Patel, & 
Manchikanti, 2011). The researchers uncovered that OIH was statistically significant 
related to the opioid therapy (Angst & Clark, 2006), since for the patients who had long-
term opioid treatment, 1) they tended to have greater levels of pain after stopping the 
long-term opioid treatment; 2) they displayed more sensitive pain response, even to 
some small procedures; 3) instead of improvement, the long-term opioid treatment 
aggravated the chronic pain for those patients (Angst & Clark, 2006). 
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In 2018, Busse et al (Busse et al., 2018) conducted a random-effects meta-
analysis to examine the harms and benefits of opioid for CNCP. They reviewed 96 
randomized clinical trials with total 26,169 patients with CNCP. The main finds were the 
opioid treatment reduced CNCP by modest 0.69 cm more than placebo. However, there 
were several problems of this study: 1) the variability among those studies were high, 2) 
the random-effects model did not address heterogeneity, 3) the study compared the 
opioid with placebo, which did not give information about the comparative effectiveness 
of opioid treatment to other alternative treatments. Overall, considering the amount of 
heterogeneity, the benefits of opioid treatment would be less or greater than this 
estimation, depending on the settings and patients. This finding should be used carefully. 
Overall, there are few evidence-based studies to show the effectiveness of long-
term opioid treatment for CNCP patients. Some clinical trials showed opioid 
medications were effective for certain CNCP patient populations for a limited time, but 
these trials lacked a comparison group. There have been no comprehensive studies to 
distinguish which target specific patient populations could benefit most of be most 
susceptible to harm by long-term opioid treatment. Plus, these studies used pain rating 
scales as the primary outcome variables, which neglected the important goal of CNCP 
management, such as changes of quality of life, restoring work ability, reducing health 
care expenditures and unnecessary health care utilization, and improved mental status.  
Evidence for the efficacy of long-term opioid treatment for CNCP is lacking, but 
studies have shown evidence for many adverse-effects, such as addiction, opioid-
induced dry mouth, nausea, and constipation (Moore & McQuay, 2005), a higher risk of 
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osteoporosis and bone fracture (A Elliott, E Opper, Agarwal, & E Fibuch, 2012),  an 
increased likelihood of diabetes (Merza, 2010), cardiac complication (Andrews et al., 
2009), immunosuppression (Brack, Rittner, & Stein, 2011), and hyperalgesia (Marion 
Lee, Sanford Silverman, Hans Hansen, & Vikram Patel, 2011). A recent study estimated 
the rates of adverse events among Veterans Health Administration patients who were 
using opioid and/or anti-inflammatory drugs found that opioid patients (who used at 
least 1 opioid between fiscal year 2011 to 2015) had a higher risk of cardiovascular 
events, acute kidney injury, gastrointestinal bleeding, and all-cause mortality than anti-
inflammatory drug users (Fassio, et al., 2018). 
Another adverse-effect that has been observed is depression among chronic 
opioid therapy recipients. Grattan et al. conducted a phone survey of 1,334 patients on 
chronic opioid therapy for CNCP. The researchers found that in patients without a 
history of substance abuse, there was a significant association between depressive 
symptoms and increased rates of self-reported opioid misuse (Grattan, Sullivan, 
Saunders, Campbell, & Von Korff, 2012). However, the measures of opioid misuse in 
the study were not sufficient extensive and internally consistent to distinguish the 
opioid-related misuse from non-pain-symptom-related misuse, such as insomnia and 
pressure of productivity loss due to the pain (Grattan et al., 2012). 
Also, different modes of administration of opioids could lead to several side-
effects. The common routes of opioid administration include oral route, enteral tubes, 
transdermal route, transdermal route, transmucosal, and aerosol (Hallenbeck, 2003). The 
oral route is the most preferred route, which is cheaper and easy to access, but it takes 
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hours for short-acting oral agents to reach peak effect and the delayed effect could lead 
to additional doses. The stacking of multiple doses could lead to overdoes (Hallenbeck, 
2003). Compared to the oral route, the enteral tubes can overcome the disadvantage of 
patients’ inability to swallow, except that the enteral tubes cannot release a long-acting 
agent (Hallenbeck, 2003). The other administration routes are relatively expensive and 
less used, such as transdermal route, transdermal route, transmucosal, and aerosol 
(Hallenbeck, 2003). Another administration route of opioid is injection.  One European 
study investigated the effects of administration of opioids via injection into in the space 
under the arachnoid membrane of the brain or spinal cord on hypothalamic-pituitary 
function during the pain treatment (Food and Drug Administration, 2011). Among 79 
patients, who received opioids for CNCP using this mode of administration, the majority 
of men and all women developed hypogonadotropic hypogonadism (Abs et al., 2000). 
In conjunction with the boost of opioid prescriptions for CNCP treatment in the 
past 2 decades, there has been increase of opioid abuse and misuse, addiction, and 
overdose deaths (Kaye et al., 2017). Some researchers estimated opioid abuse in the U. 
S. population, which was present in 6.7 to 8 per 10,000 insured population and 2.1% of 
persons aged 12 or older in 2007 (Substance Abuse and Mental Health Services 
Administration, 2009). Based on community practice surveys, Korff et al. estimated the 
overall opioid misuse rate is around 4% to 26% (Von Korff, Kolodny, Deyo, & Chou, 
2011). Cepeda et al. have done a study with over 25 million patients during 18-months 
and found 0.3% patients exposed to opioid showing doctor shopping behavior (M. S. 
Cepeda et al., 2013; M Soledad Cepeda, Fife, Chow, Mastrogiovanni, & Henderson, 
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2012). Fishbain et al. reviewed 67 studies and assessed the abuse or addiction rate is 
3.27% for chronic pain patients with nonmalignant pain who were exposed to long-term 
opioid treatment (Fishbain, Cole, Lewis, Rosomoff, & Rosomoff, 2007).  
The most serious adverse-effect of long-term opioid treatment is opioid-related 
overdose deaths. Annually, in the United States, there are more than 16,000 deaths of 
opioid-related causes (Kaplovitch et al., 2015). A recent study estimated the rates of 
opioid overdose death was 7.9 per 100,000 in 2013 and increased to 9.0 per 100,000 in 
2014 (Rudd, Aleshire, Zibbell, & Matthew Gladden, 2016). This study also reports the 
increase in death rates for natural and semisynthetic opioids, which was 9% and 80%, 
respectively (Rudd et al., 2016). As opioid abuse and misuse, addiction, and overdose 
deaths increase, the related medical expenditures and societal costs also rise 
consequently. 
1.1.3 Medical expenditures and economic burden of CNCP 
The cost of opioid abuse is enormous in both in terms of medical care costs and 
other societal costs. There are many studies estimating the chronic pain and CNCP 
related medical utilization and expenditure (Chung, Zeng, & Wong, 2013; Gaskin & 
Richard, 2012; Hamza et al., 2012; Lam, Zheng, Davila, & et al., 2011; Maeng et al., 
2017; Manchikanti et al., 2012; Riley, Eisenberg, Müller-Schwefe, Drewes, & Arendt-
Nielsen, 2008; Dennis C Turk, 2002; Dennis C. Turk & Okifuji, 1998) (Kern et al., 
2015) (Lam et al., 2011; Smith, 2010; Smith, Davis, Stano, & Whedon, 2013; Soni, 
2011). According to Gaskin & Richard, the total US health care costs of pain is around 
$629 to $713 billion in 2008 inflated to 2017 dollar’s value (Gaskin & Richard, 2012). 
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Based on the 2009 Medical Expenditure Panel Survey (MEPS), they estimated the 
money value of lost productivity for pain conditions is around $342 billion in 2017 
dollar’s value (Gaskin & Richard, 2012). The annual total direct health care cost and 
indirect social cost for pain conditions are greater than the annual cost of heart disease, 
cancer, and diabetes (Gaskin & Richard, 2012). However, the Gaskin and Richard’s 
research was a general estimation for all pain conditions, which did not distinguish the 
expenditures between chronic pain and acute pain and did not assess the costs for 
different treatments. 
The Agency for Healthcare Research and Quality (AHRQ) investigated the 
health care use and expenditures for adult women with pain conditions. Its statistical 
brief #342 shows that the average medical expenditures for women with pain conditions 
($11,472 in 2017 dollars) were more than twice the expenditures for women without 
pain conditions ( $4,741 in 2017 dollars) (Soni, 2011). Total health care expenditures for 
women for pain treatment were $12.9 billion ($14 billion in 2017 dollars) and total 
expenditures for prescription medicines to treat pain conditions among adult women 
were $2.4 billion ($2.6 billion in 2017 dollars) (Soni, 2011). Soni’s report used the 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) 
diagnosis codes to identify pain condition measures, which might not precisely capture 
the chronic pain conditions. Also, Soni did not compare the difference in health care 
expenditures for opioid treatment as distinct from other treatments for pain conditions.  
In a recent retrospective cohort study, Kern et al. investigate the treatment 
patterns, healthcare utilization, and treatment cost before and after initiation of opioid 
 17 
 
treatment. Using claims data from 2007 till 2011, their study included around 2.9 million 
patients initiating opioid therapy. Most of the study patients (93%) had a duration of 
opioid therapy of 30 to 182 days, whereas 7% had long-term opioid therapy, defined as a 
duration of more than 182 days (Kern et al., 2015). Compared to the pre-opioid-therapy 
period, healthcare utilization increased during the first 6 months of opioid therapy, 
followed by a decrease after the first 6 months of therapy, though remaining higher than 
healthcare use before opioid treatment (Kern et al., 2015). Total all-cause costs followed 
a similar pattern., During the 12 months prior to initiation, costs were $13,459 ($13,900 
in 2017 dollars) per patient/ per year, which increased to $31,695 ($32,724 in 2017 
dollars) during the first 6 months of therapy, dropping to $ 20,705 ($21,384 in 2017 
dollars) after first 6 months of therapy (Kern et al., 2015). One of the major cost drivers 
was inpatient hospitalization cost, which almost doubled from $7,911 ($8,170 in 2017 
dollars) before initiation to $12,895 (13,318 in 2017 dollars) for the first 6 months of the 
opioid therapy (Kern et al., 2015).  
A strength of this study is that it is based on large claims data with 4 years 
follow-up time to examine resource use and cost for individual patients before and after 
the initiation of opioid treatment, as well as the use of a study design that stratified 
patients into groups defined as short-term and long-term opioid therapy and weak and 
strong opioid users. Plus, the results of the study provided evidence of an increase in 
health care utilization and cost after the initiation of opioid treatment. However, the 
results should be interpreted carefully since it is an observational study, and as such the 
authors could not conclude whether the increase in utilization and cost was caused by 
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opioid therapy or other underlying confounders. Moreover, the data was from employer-
provided health plans and conclusion can only apply to the similar demographic 
population. Additionally, for the estimation of opioid abuse and addiction, as well as the 
“doctor shopping”, there is no extra data besides the claims record to assess the full 
impact of opioid abuse. 
Some studies tried to evaluate the social and medical burden of opioid therapy 
related adverse-events, such as the cost of opioid abuse (Kirson et al., 2017; Scarpati et 
al., 2017), misuse and overdose death (Smith, 2010) (Maeng et al., 2017; McLellan & 
Turner, 2010; Modarai et al., 2013; Rudd et al., 2016).  The office of national drug 
control policy estimated the economic cost of opioid drug abuse in the United States was 
at $193 billion in 2007 and $120 billion in lost productivity, $11 billion in healthcare 
costs, as well as $61 billion in criminal justice costs (Policy, 2011). Previous work has 
documented that opioid abusers are more likely to be associated with multiple 
comorbidities and their medical costs are 8 times higher than non-abusers ($15,884 vs. 
$1,830) (Manchikanti & Singh, 2008). Baser et al. used the 2006 to 2010 national 
Veterans Health Administration (VHA) data to estimate the annul healthcare cost for 
patients with opioid prescription, which is $25,197 vs. $6,350 without opioid 
prescription; and $28,882 for the patients with diagnosis of the opioid abuse vs. $13,605 
for non-abuser (Baser et al., 2014). Meyer et al. did a literature review based on studies 
published during 2002- 2012, and found the annual additional health cost for private 
insured opioid abuser are from $14,054 to $20,546, and $5,874 to $15,183 for Medicaid 
opioid abuser (Meyer, Patel, Rattana, Quock, & Mody, 2014).  
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Kirson et al. tried to explore the drivers of the excess cost of opioid abuse over an 
18-month study time by using private insurance administrative claims data (Kirson et al., 
2017). The study identified opioid abuser and non-abuser and matched two groups using 
propensity scores adjusted for demographic, clinic, and health care resources utilization. 
The study compared the health care utilization and cost for abuser and non-abuser in 
three-time periods: baseline (7-12-month pre-abuse diagnosis), pre-index (1-6 months 
pre-abuse diagnosis), and 6 month post abuse diagnosis. The outcomes showed excess 
costs appeared 5 months before opioid abuse diagnosis and peaked at the first month 
after diagnosis (Kirson et al., 2017). The major driven factors for excess costs 5-month 
before diagnosis include non-opioid drug and alcohol abuse treatment (Kirson et al., 
2017). And the excess cost driven factors for post-diagnosis include “opioid and other 
substance abuse disorder, mental health conditions, and painful conditions” (Kirson et 
al., 2017). The mean incremental healthcare cost is $14,810 per patient/ per year for 
opioid abuser.  
They also did a 24-month follow-up analysis and the results showed during the 
extra 18-month follow-up period, the excess cost did not return to baseline level and 
raised up to $7,346 per patient/ per year (Scarpati et al., 2017). These studies suggest the 
opioid abuse related costs are also driven by other substance abuse even before the initial 
diagnosis of opioid abuse, and the excess cost will last for a more than 1-year follow-up 
time. Thus, the management of opioid treatment should be in the context of patient’s 
history of substance abuse and should be followed for a longer time. However, these 
studies applied to all the opioid treatment, which did not distinguish the short or long-
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term therapy, weak or strong opioid prescription, and for CNCP or for cancer related 
pain conditions. 
Overall, there were some studies estimating the healthcare expenditures and 
social cost for the CNCP conditions and disclosed great burden caused by the conditions. 
Other studies compared total medical expenditures for groups with and without opioids 
treatments and showed associations between increase of healthcare utilization/ 
expenditure and initiation of opioid treatment (Kern et al., 2015; Soni, 2011).  
Additionally, some studies focused on the cost driven factors for opioid abuse and tried 
to assess the utilization and cost change pre and post the diagnosis of opioid 
abuse/misuse (Kirson et al., 2017; Scarpati et al., 2017). Nevertheless, these studies used 
private insurance claims data and could not represent the general population. There is 
one study that used 2008 national representative data (MEPS) to estimate the economic 
burden of pain in U.S. civilian noninstitutionalized population (Gaskin & Richard, 
2012).  Since MEPS is a self-reported survey data that might have potential authenticity 
problems for the answers of the survey questions, and the outcomes from this dataset 
have not been verified by other data sources, as well as no update since 2008. Besides, as 
many other studies, the estimation were based on the chronic pain patients and did not 
specify the study cohort as the CNCP patients. So, in my analysis, I will use both self-
reported data and claims data to evaluation the health outcome and economic impact of 
CNCP conditions and opioid treatment for general population, in both cross sectional 
and longitudinal studies. 
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1.2 Research Plan 
1.2.1 Research Questions  
In this retrospective study, I examined total medical care use and expenditures 
for CNCP conditions based on the 2011 Medical Expenditure Panel Survey data and the 
2008-2012 Texas Blue Cross and Blue Shield claims data. The research aims were to: 
1) Compare the mean annual total healthcare utilization and overall healthcare 
expenditures for CNCP patients with and without opioids prescription/ therapy 
after the Propensity Score (PS) matching (MEPS data), and in the cross-sectional 
multivariate regression model (BCBS data) 
2) Estimate annual total healthcare utilization and expenditures change for patients 
with new developed CNCP condition by the longitudinal model 
3) Assessed annual total healthcare utilization and expenditures change for CNCP 
patients with new initiated opioid treatment episode by the longitudinal analysis 
1.2.2 Conceptual Framework  
In this retrospective cohort study, I identified patients with CNCP conditions 
using ICD diagnosis codes and SF-12 pain questions. I used emergency department (ED) 
visits and inpatients admission as the outcome measures to compare the healthcare 
utilization. I calculated total medical expenditure by summing all the payments from the 
individual’s out-of-pocket payments and all third-party (insurance) payments.  
To estimate the impact of CNCP condition and opioid treatment on total 
healthcare expenditure, I adopted Aday and Andersen’s behavioral model of health 
service use as the conceptual framework (Andersen, 1995). This framework had been 
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used for numerous previous studies and validated in many different contexts for different 
health services and populations. According to the framework, the health expenditures 
associate with “predisposing, enabling, and perceived health need factors” (Andersen, 
1995). The predisposing factors in my analysis included age, race, gender, education, 
health behaviors (smoke, exercise) and marital status. The enabling factors of my model 
were income, health insurance status, and location. The perceived health need factors 
adjusted for different health status and other chronic conditions that might influence the 
medical expenditure. I included self-reported health status (good, fair, poor) and 
hypertension, heart disease, emphysema, and diabetes as the enabling factors. The 
preliminary model included all the factors; but I only kept the statistically significant 
factors in the final model. 
1.2.3 Data Source and Analytical Plan  
This study used both self-reported survey data (CY2001-CY2011 MEPS) and 
private insurance claims data (CY2008- CY2012 Texas Blue Cross and Blue Shield). 
The MEPS data collected extensive information about health conditions, people’s health 
behaviors, and health utilization and expenditures. It followed subjects for five panels in 
two years, which enabled the longitudinal analysis design. As a complement to the self-
reported survey data, the Texas Blue Cross and Blue Shield claim data provided 
objective record for health conditions and utilization, which increased the validity and 
reliability of the results.  
The cross-sectional analysis was based on a propensity score (PS) matching 
approach for the MEPS data to examine the difference of health care expenditures 
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between the opioids group and the non-opioids group adjusting for all known 
confounders. For the BCBSTX data, the expenditure was modeled by a GLM model 
with log link gamma distribution to assess the impact of independent variables due to the 
right skewed distribution for medical expenditure.  
For the longitudinal analysis, I adopted the generalized linear mixed-effects 
model (GLMMs) for mass-univariate data. The GLMMs allowed both fixed and random 
effects treating patient-specific intercepts and linear change with time as random effects. 
This approach allowed me to assess the long-term opioid treatment (the key fixed effect) 
on the average change in total annual medical expenditure while accounting for the 
dependence of within-patient repeated measures over time.  
The mixed-effect models included age (continuous), sex (male and female), race 
(white, black, Hispanic and other), marital status (married or not), poverty level (low and 
middle/high income), education (high school or less and college or higher), insurance 
(any private insurance, any public insurance, and uninsured), smoking (yes or no), MSA 
(yes or no), BMI (underweight, normal, overweight, and obesity), health status 
(excellent, very good, good, fair, and poor), comorbidity (high blood pressure, heart 
disease, stroke, emphysema, chronic bronchitis, asthma, high cholesterol, diabetes, joint 
pain, and arthritis), treatment status (treatment or control group).  
Based on previous studies, all the data for medical expenditure were presented as 
least-squares means (95% confidence interval [95% CI]). There was less covariates 
adjustment for BCBSTX data, due to the data limitation.  
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The expected outcomes included the difference of health expenditure among 
CNCP patients with long-term opioid treatment group and non-opioid treatment group. 
The results would be informative for the policy makers, insurance payers, physicians, as 
well as the patients to balance the need of treating chronic pain and minimizing the risk 
of opioid treatment, avoiding unnecessary health expenditure. 
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CHAPTER 2. UTILIZATION AND COST ANALYSIS OF MEPS  
 
In this chapter, I used 2011 MEPS data to compare the annual total health 
expenditure for CNCP patients with and without long-term opioid treatments. The main 
research question was to assess whether there were higher health expenditures for 
patients receiving long-term opioid treatment, and the scale of the difference. In order to 
compare the opioid and non-opioid samples while adjusting for demographic, SES and 
clinical characteristics, I adopted the Propensity Score (PS) matching approach and 
adjusted for age, gender, race, marital status, poverty level, education, insurance, 
smoking behavior, physical activity, MSA, BMI, and comorbidity status. These 
covariates were compared before matching and after matching to evaluate the 
successfulness of the PS matching algorithm, and finally the average treatment effect of 
opioids use on health expenditure was estimated based on the matched samples.   
 
2.1 Data 
2.1.1 Overview of MEPS Data 
Conducted by the Agency for Healthcare Research and Quality (AHRQ) and the 
National Center for Health Statistics, MEPS is a nationally representative survey for 
health care use, expenditures, sources of payment, and health insurance coverage of the 
U.S. civilian non-institutionalized population since 1996.  The MEPS data adopts an 
overlapping panel design. Each panel of respondents is surveyed through five rounds in 
two years. MEPS has the Household Component (HC) which draws samples from prior 
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years’ National Health Interview Survey, and the Insurance Component (IC) which 
collects data from Health Insurance Cost Study. Each year, MEPS selects one new panel 
of survey respondents.  Each panel has several rounds of surveys covering during two 
full calendar years (see Figure 1). This design assures the continuous presence of 
repeated survey measures in the MEPS data, which is essential for estimation of the 
expenditure model. (The data for generating the figure 1 was retrieved from 
https://meps.ahrq.gov/survey_comp/hc_data_collection.jsp) 
 
 
Figure 1 MEPS Panel Design: Data Reference Periods. 
 
 
The 2011 MEPS data covered the Round 3 and 4 for MEPS Panel 15 and Round 
1, 2 and 3 for Panel 16. The combined 2011 MEPS provided a nationally representative 
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sample of the civilian noninstitutionalized population of the United States in this 
calendar year. The sample was based on complex stratified multi-stage probability 
design to represent national population. The unweighted response rate was 54.9%. The 
MEPS data assigned a person-level weight to each survey participant to adjust the 
nonresponse and population features.   
This study used both the Household Component (HC) and Medical Provider 
Component (MPC). The MEPS-HC included demographic characteristics, health 
expenditures, health conditions, health status, utilization of medical services, access to 
care, health insurance coverage, and family and individual income, among other 
variables. The sample contained 13,449 households and 33,622 individuals’ records.  
Additionally, by directly collecting data from respondents’ providers and 
pharmacies, the MEPS-Medical Provider Component files provided detailed expenditure 
information of medical events and pharmacy records.  
The 2011 Medical Conditions file (HC146) contained reported current medical 
conditions for the survey sample in the calendar year. If a condition had not been 
diagnosed before the survey data or was currently experienced, it was defined as the 
current condition. The file contained 108,619 medical records and 35 variables, 
including the ICD-9 diagnosis and procedure codes, as well as the clinical classification 
codes, which were aggregated and mutually exclusive clinical classification category 
codes. The 2011 Prescribed Medicines file (HC-144A) recorded 3,123,747 unique 
prescribed medicine events and associated expenditures, as well as the medical 
conditions. 
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2.1.2 MEPS Sample selection  
To generate the sample for this analysis, I merged the Medical Conditions file 
(HC-146) and Prescribed Medicines file (HC-144A) with the person-level MEPS-HC 
dataset, by using the MEPs linked files. After merging, I applied the following inclusion 
and exclusion restrictions: the primary inclusion criteria related to identifying patients 
with diagnosis codes indicative of all chronic pain conditions, and the main exclusion 
criteria were a current diagnosis of cancer or a prior cancer condition which was defined 
as with ICD-9 diagnosis code of 140.00-209.36, 209.70-209.79, 511.81, 789.51 
(ICD9Data, 2012). Also, for the opioid treatment, I used the prescription files to flag 
prescriptions for all opioid drugs. The flow-chart figure 2 in the result section showed 
the sample selection process. 
To fully capture all the CNCP conditions, I used both self-reported chronic pain 
condition from survey sections in the MEPS, and the claim records for the CNCP 
diagnosis from the medical event file. For the self-reported CNCP, there were two 
sources: SF-12 questionnaire (Antaky, 2016) and the Priority Conditions section of the 
MEPS-HC Questionnaire Sections. For the claim medical event record, all the CNCP 
were identified by ICD-9 diagnosis code. 
In the MEPS-HC SF-12 questionnaire, there was the pain related question 
“During the past 4 weeks, how much did pain interfere with your normal works 
including work outside the home and housework. The options were: extremely, quite a 
bit, moderately, a little bit, and not at all (AHRQ, 2013). This question had been asked 
twice at round 4 in Panel 15 and round 2 in Panel 16 and generated a variable 
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ADPAIN42, of which the value reflects the answers in both rounds. If the answer was 
extremely, quite a bit, or moderately, it was considered a chronic pain condition (AHRQ, 
2013). 
The other self-reported CNCP condition was captured by the answer of Priority 
condition survey joint pain questions, which asked if the person (aged 18 or older) had 
experienced pain, swelling, or stiffness around a joint in the last 12 months (AHRQ, 
2013). This question had been asked twice at round 3 in Panel 15 and round 1 in Panel 
16, also at round 5 in Panel 15 and round 1 in Panel 16. Any “yes” answer to this 
question was coded as chronic pain conditions (AHRQ, 2013). 
Additionally, the study selected CNCP conditions by using the ICD-9 diagnosis 
codes and HCPCs/CPT codes from the medical events files. The patients were flagged as 
CNCP as long as they had one of the following ICD-9 diagnosis code in in table 1 and 
one of the HCPCs code. All the codes to flag CNCP conditions were from previous 
studies (Cardarelli et al., 2017; Chang, Ma, Lee, & Hsieh, 2015). 
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Table 1 ICD-9 Diagnosis codes and HCPCs codes to flag CNCP conditions. 
ICD-9 Diagnosis code 
Code  Description 
338.x Pain, Not Elsewhere Classified 
524.62 TMJ Arthralgia 
569.42 Anal or Rectal Pain 
524.x Dent Facial Anomalies Including Malocclusion 
595.x  Cystitis 
617.x Endometriosis All 
625.x Pain and Other Symptoms Associated with Female Genital Organs 
711 -714 Arthritis 
715.x Osteoarthritis 
716.6-716.9 Monoarthritis Arthropathy 
716.91 Arthropathy Nos-Shlder 
716.97 Arthropathy Nos-Ankle 
719.41 Joint Pain-Shlder 
719.43 Joint Pain-Forearm 
719.45 Joint Pain-Pelvis 
719.46 Joint Pain-L/Leg 
719.47 Joint Pain-Ankle 
719.49 Joint Pain-Mult Jts 
720.0x–721.3x Ankylosing Spondylitis and Other Inflammatory Spondylopathies 
72210 Lumbar Disc Displacement 
722.0x, Displacement of Cervical Intervertebral Disc Without Myelopathy 
722.32, Schmorl'S Nodes 
722.52, Degeneration of Lumbar or Lumbosacral Intervertebral Disc  
722.73, Intervertebral Disc Disorder with Myelopathy, Lumbar Region 
722.83, Postlaminectomy Syndrome, Lumbar Region 
722.93, Other and Unspecified Disc Disorder, Lumbar Region 
723.1 Cervicalgia 
724.1 Pain in Thoracic Spine 
724.2 Lumbago 
724.3 Sciatica 
724.5 Backache Nos 
724.02, Spinal Stenosis, Lumbar Region, Without Neurogenic Claudication  
724.2x, Lumbago 
724.3x, Sciatica 
724.6x Disorders of Sacrum 
724.7x Chronic Lower Back Pain 
725 Polymyalgia Rheumatica 
726.33 Olecranon Bursitis 
726.71 Achilles Tendinitis 
7270.6 Tenosynovitis Foot/Ankle 
728.85 Spasm of Muscle 
729 Fibromyalgia  
729.x Other Disorders of Soft Tissues 
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Table 1 (continued) 
ICD-9 Diagnosis code 
729.1 Myalgia and Myositis Nos 
729.5 Pain in Limb 
729.82 Cramp in Limb 
729.89 Muscskel Sympt Limb Nec 
780.7  Malaise and Fatigue 
784.1 Throat Pain 
784.92 Jaw Pain 
780.x 
General Symptoms (Symptoms, Signs, And Ill-Defined 
Conditions 780-799) 
840.4 Sprain Rotator Cuff 
840.8 Sprain Shoulder/Arm Nec 
840.9 Sprain Shoulder/Arm Nos 
841.8 Sprain Elbow/Forearm Nec 
847 Sprain of Neck 
847.2 Sprain Lumbar Region 
848.8 Other Sprains Strains 
842 Sprain of Wrist Nos 
845.09 Sprain of Ankle Nec 
845.1 Sprain of Foot Nos 
845.19 Sprain of Foot Nec 
HCPCs code (ICD-9 with one of the following) 
99201-99205 Evaluation and Management 
99212-99215 Evaluation and Management 
99241-99245 Evaluation and Management 
99385 Evaluation and Management 
99387 Evaluation and Management 
99395-99397 Evaluation and Management 
99402-99404 Evaluation and Management 
 
Last, in order to exclude the cancer patients, the study eliminated all individuals 
with prior cancer conditions or a current diagnosis of a variety of cancer. The current 
diagnosis of cancer was identified by the ICD-9 codes and the MEPS Clinical 
Classification Codes (CCCODEX). The ICD-9 cancer diagnosis code was flagged by the 
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CMS definition, of which the ICD-9-CM range for cancer was 140.00-209.36, 209.70-
209.79, 511.81, 789.51. The MEPS CCCODEX code was generated by aggregate the 
ICD-9 diagnosis code to mutually exclusive categories. The cancer condition is in the 
CCCODEX range 11-45 (Chang, Ma, Lee, & Hsieh, 2015).  
 
2.2 Methods 
The objective of the analysis in this chapter was to estimate the differential in 
medical expenditures associated with the presence or absence of prevalent opioid 
treatment among patients with CNCP, accounting for differences in patient 
characteristics that might affect utilizations and medical expenditures. 
2.2.1 Medical Expenditures  
Medical expenditure in MEPS referred to payments for health care services 
including individuals’ out-of-pocket payments, private insurance payments, Medicaid, 
Medicare and other payment sources for all inpatient, outpatient, and professional 
services, as well as for pharmaceuticals and devices. MEPS data excluded payments for 
over-the-counter drugs. In this study, total health care expenditures were the sum of 
expenditures for office visits, hospital outpatient visits, ambulatory visits, hospital 
emergency room visits, hospital inpatient stays, and prescribed medicines, as well as 
other medical equipment, devices and services. 
2.2.2 Current Opioid Use 
Opioid drugs were categorized using national drug codes (NDC).  The drugs 
were considered as opioid treatments including Buprenorphine, Butorphanol, Codeine, 
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Dihydrocodeine, Fentanyl, Hydromorphone, Levomethadyl, Levorphanol, Meperidine, 
Methadone, Morphine, Opium, Oxycodone, Oxymorphone, Pentazocine, Propoxyphene, 
Tapentadol, Tramadol. The final opioid prescriptions list included 13,270 opioid drugs 
(NIDA, 2018), which could be downloaded from 
http://www.pdmpassist.org/pdf/Conversion%20Reference%20Table.xlsx. Current opioid 
users were defined as patients with prescription of continuously opioid drugs more than 
3 months in calendar year 2011.  Non-opioid users were defined as patients with no 
opioid prescriptions or less than 3 months continues opioid prescription in 2011. 
2.2.3 Covariates 
The medical expenditure comparison between opioid user group and non-opioid 
user group needed to consider the impact of some medical conditions/ comorbidities, 
demographic factors and socioeconomic status.  Also, CNCP as the major predictor was 
often affected by psychological and socio-environmental factors (Furlan et al., 2006). In 
this paper, to adjust for the potential confounders, I included following covariates: 
gender, age, race/ethnicity, marital status, education, income, insurance status, MSA 
residents or not, smoking status, physical activity, weight and obesity, general health 
status (excellent, very good, good, fair, and poor), and eight health conditions indicators: 
high blood pressure, heart disease, stroke, emphysema, chronic bronchitis, high 
cholesterol diagnosis, diabetes, and arthritis. 
2.2.4 Statistical Analysis 
In the comparison of medical expenditures between the opioid treatment group 
and non-opioid treatment group, I adopted the propensity score (PS) approach to address 
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potential confounding related to treatment selection (i.e., CNCP patients treated with 
opioids might have more severe pain than those not treated with opioids). The PS 
approach entailed estimating the likelihood that a CNCP pain patient received opioid 
treatment based on the patient’s observed characteristics. The fundamental assumption 
of the PS method is “Strong Ignorability” (Rosenbaum & Rubin, 1983), which assumes 
that observed baseline covariates were sufficiently comprehensive, so that the impact of 
any unobserved confounder was small enough to be ignored for both treatment 
assignments and outcomes (Rosenbaum & Rubin, 1983).  
Thus, the propensity score for each patient was determined by a treatment 
assignment logistic regression model, where the dependent variable was the receipt of 
opioids (yes or no), and the independent variables were assumed to affect both opioid 
treatment choice and medical expenditure outcomes, specifically age, gender, 
race/ethnicity, marital status, education, income, insurance status, smoking status, 
physical activity, weight and obesity, diabetes, asthma, general health status, and MSA 
region indicators. 
CNCP individuals with and without opioid treatment were matched according to 
propensity scores. After running bivariate test of each matching variable and treatment 
variable, the next step was to create the propensity score by log odds of predicted 
probability, followed by checking the balanced propensity score across opioid and non-
opioid groups. The PS matching was conducted using STATA/PSMATCH2 and based 
on nearest neighbor matching within caliper and without replacement (Leuven & 
Sianesi, 2018).  As recommended by Rosenbaum and Rubin, a caliper size equal to one 
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quarter of the standard deviation of the propensity score distribution for the entire study 
sample was used (Rosenbaum & Rubin, 1985).   
After matching, I assessed the matching quality by using standardized bias and 
Standardized Mahalanobis metric distance. For continuous variables, the standardized 
difference in % was calculated to reflect the difference of mean between two groups for 
each covariate, which was 
𝑑 = 100
(𝑥𝑝̅̅ ̅ − 𝑥?̅?)
√{(𝑆𝑃
2 + 𝑆𝑡
2)/2}
 
where for each covariate 𝑥𝑝̅̅ ̅ and 𝑥?̅? are the sample means and 𝑆𝑃
2 and 𝑆𝑡
2 are the 
corresponding sample variance (Rosenbaum & Rubin, 1985). For dichotomous 
variables, the standardized difference is defined as: 
𝑑 = 100
(𝑝𝑝 − 𝑝𝑡)
√{(𝑝𝑝(1 − 𝑝𝑝) + 𝑝𝑡(1 − 𝑝𝑡))/2}
 
where 𝑝𝑝 is the proportion of treatment group and 𝑝𝑡 is the proportion of control group. 
Also, for categorical variables with K levels, I adopted a multivariate 
Mahalanobis distance method to generalize the standardized difference metric to handle 
a multinomial sample (Stuart, 2010). Let  
T = (𝑃12̂, 𝑃13̂, … 𝑃1𝑘)̂ ′ 
C = (𝑃22̂, 𝑃23̂, …𝑃2?̂?)′ 
 𝑃1?̂? = Pr( 𝐶𝑎𝑡𝑒𝑔𝑜𝑟𝑦 𝑘 | 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑡 𝑔𝑟𝑜𝑢𝑝 𝑗) 
 𝑗 ∈ {1,2} 
𝑘 ∈ {2,3, … , 𝐾}.  
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The standardized Mahalanobis metric difference is then defined as 
𝑑 = √(𝑇 − 𝐶)′𝑆−1(𝑇 − 𝐶) 
where S is a (𝑘 − 1) × (𝑘 − 1) covariance matrix, which is defined as 
𝑆 = [𝑆𝑘𝑙] =
{
 
 
[?̂?1𝐾(1 − ?̂?1𝐾) + ?̂?2𝐾(1 − ?̂?2𝐾)]
2
 , 𝑘 = 𝑙
[?̂?1𝐾?̂?1𝑙 + ?̂?2𝐾?̂?2𝑙]
2
 , 𝑘 ≠ 𝑙
 
The empirical criterion of excellent matching was standardized bias less than 5%, 
while bias less than 10% generally was considered adequate (Austin, 2011, p. 412).  
Based on the matched sample, bivariate analyses were used to establish 
demographic and clinical variables associated with the outcome. Differences between 
groups were assessed with χ2 or Fisher’s exact test for categorical variables, and Student 
t-test or Wilcoxon rank-sum test for continuous variables. 
 
2.3 Results 
The original 2011 MEPS data included 35,313 individuals. After excluding 
individuals with the prior condition of cancer and current diagnosis of cancer, there were 
33,158 people. By using the SF-12 questionnaire and ICD-10 code, I identified 11,858 
people in the final CNCP sample, of which 979 individuals had opioid treatments.  
Figure 2 shows the sample selection flowchart. 
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Figure 2 MEPS Cross-sectional Analysis Cohort Selection Flowchart. 
 
 
The table 2 showed the results of propensity score before and after PS-match 
covariate balance (bias) statistics, and the comparison of each covariate between 
individuals using or not using opioids treatments. Before matching, there were 11,503 
individuals in non-opioid treatment group and 979 in treatment group.  All 979 treatment 
patients were patients were matched to 979 patients from the pool of patients in the non-
opioid treatment group.  Table 2 included the mean or percent comparison of all the 
covariates for opioid and non-opioid groups before PS matching. There were several 
covariates statistically significant different between treatment and control group before 
the PS-match, which included race, married or single, income level, insurance type, 
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smoking status, physical activity, and some chronic conditions. The standardized 
difference for those covariates ranged from 4% to 54%. The initial differences between 
opioid and non-opioid groups were large. 
 
Table 2 A Group Comparison before PS matching for MEPS Cross-sectional 
Analysis. 
  
Non-Opioids Opioids Two-sample 
t-statistics 
Distance** 
(n=11,503) (n=979) 
Variables Mean Or % 
Mean 
Or % 
P-value   in % 
Age 46.49 49.31 0.01 15% 
Gender     
   Female 58% 56% 0.54 4% 
Race/ Ethnicity*     
   White 49% 56%   
   Black 21% 25%   
   Hispanic 22% 11%   
   Other 8% 8% 0.00 29% 
Marital Status*     
   Married 63% 58% 0.02  
Poverty/Income*     
Poor/ Low  45% 49%   
Middle/High  55% 51% 0.04 9% 
Education     
   High School or less 63% 57%   
College or Higher 37% 43% 0.23 11% 
Insurance*     
Any Private Insurance 55% 56%   
Any Public Insurance 31% 34%   
Uninsured 14% 10% 0.02 17% 
Smoking* 21% 30% 0.00 6% 
Physical Activity* 45% 36% 0.00  
BMI         
   Underweight   3% 2%   
   Normal Weight               28% 25%   
   Overweight               32% 33%   
   Obesity               37% 40% 0.59 19% 
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Table 2 (continued)     
  Non-Opioids Opioids Two-sample 
t-statistics 
Distance** 
 (n=11,503) (n=979)  
Variables Mean Or % Mean Or % P-value   in % 
MSA 85% 84% 0.33  
High Blood Pressure  16% 13% 0.24  
Heart Disease* 18% 26% 0  
Stroke* 5% 11% 0  
Emphysema * 3% 5% 0.02  
Chronic Bronchitis* 5% 8% 0.04  
Asthma 12% 15% 0.05  
High Cholesterol 39% 41% 0.42  
Diabetes 16% 15%   
Joint pain* 79% 85% 0.04  
Arthritis* 39% 61% 0 44% 
Health Status*     
Excellent 13% 5%   
Very Good 34% 24%   
Good 34% 31%   
Fair 16% 28%   
Poor 3% 12% 0 54% 
*P-value<0.05 
  **The difference measure is the mean difference as a percent of the average standard deviation for continuous or  
  dichotomous variables and as the standardized Mahalanobis metric distance for K-level categorical variables 
     
 
After estimating the propensity scores, the box-plots in Figure 3 showed the 
difference for two groups before matching. The range of the propensity score for the 
opioid group was much wider than the range for the non-opioid group, but there was 
considerable overlap in the two distributions which provides a broad range of support for 
propensity score matching. 
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Figure 3 Boxplots of Estimated PS Scores. 
 
 
Similar as the table 2, the table 3 included the mean or percent comparison of all 
the covariates for opioid and non-opioid groups after PS matching. There were several 
covariates statistically significant different between treatment and control group after the 
PS-match, which included race, married or single, income level, insurance type, smoking 
status, physical activity, and some chronic conditions. The standardized difference for 
those covariates ranged from 4% to 43%. The after matching differences between opioid 
and non-opioid groups were reduced, but balance remained poor for some individual 
covariates, particularly for arthritis, which is the comorbid condition most directly 
related to the need for long-term opioid treatment. 
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Table 3 A Group Comparison after PS matching. 
  
Non-Opioids Opioids Two-sample 
t-statistics 
Distance  
(n=979) (n=979) 
Variables Mean Or % Mean Or % P-value  in % 
Age 49.75 49.82 0.93 4% 
Gender 
    
   Male 42% 44% 
  
   Female 58% 56% 0.54 5% 
Race/ Ethnicity* 
    
   White 50% 48% 
  
   Black 22% 24% 
  
   Hispanic 20% 19% 
  
   Other 8% 9% 0.00 24% 
Marital Status* 
    
Current Married 50% 44% 
  
    Current Single 50% 56% 0.02 8% 
Poverty* 
    
Poor/ Low income 44% 49% 
  
Middle/High income 56% 51% 0.04 4% 
Education 
    
   High School or less 60% 57% 
  
College or Higher 40% 43% 0.23 13% 
Insurance* 
    
Any Private Insurance 57% 57% 
  
Any Public Insurance 28% 33% 
  
Uninsured 15% 10% 0.02 9% 
Smoking 21% 30% 0 5% 
Physical Activity* 45% 36% 0 
 
MSA 85% 84% 0.33 
 
BMI 
    
   Underweight 2% 2% 
  
   Normal Weight 28% 25% 
  
   Overweight 33% 33% 
  
   Obesity 38% 41% 0.59 16% 
High Blood Pressure 16% 13% 
 
19% 
Heart Disease* 18% 26% 0.03 11% 
Stroke* 5% 11% 0.02 10% 
Emphysema * 3% 5% 0.02 10% 
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Table 3 (continued)  
  
Non-Opioids Opioids Two-sample 
t-statistics 
Distance  
(n=979) (n=979) 
Variables Mean Or % Mean Or % P-value  in % 
Chronic Bronchitis* 5% 8% 0.04 4% 
Asthma 18% 15% 0.05 10% 
High Cholesterol 20% 15% 0.42 14% 
Diabetes 16% 15% 0.59 3% 
Joint pain* 79% 85% 0.04 14% 
Arthritis* 39% 41% 0 43% 
Health Status* 
    
Excellent 11% 9% 
  
Very Good 33% 38% 
  
Good 35% 31% 
  
Fair 18% 19% 
  
Poor 3% 4% 0.1 13% 
*P-value<0.05     
 
Table 4 provides summary of the percent reduction in bias for categories of 
covariates after the matching. Matching reduced the bias for age by 73%, 88% for 
gender, 39% for race, 67% for marital status, 11% for poverty and 18% for education. 
There also was a decrease in bias for the health-related covariates, such as comorbidities 
and health status. There was adequate covariate balance for most of the categories of 
covariates. Overall, the PS-matching substantially reduced bias across groups. 
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Table 4 Reduction % in Bias for Demographic Variables. 
  Initial Bias 
Bias after 
matching 
Per cent** 
reduction 
Age** 15% 4% 73% 
Race/Ethnicity** 29% 14% 52% 
Marital Status* 11% 8% 27% 
Poverty* 9% 4% 56% 
Insurance* 17% 9% 47% 
Comorbidities** 28% 8% 71% 
Health** 54% 13% 76% 
*Compared the reduction of Standardized Mahalanobis metric distance 
**P-value<0.05 
 
I compared total medical expenditures between the opioid and non-opioid groups 
in the propensity-score matched sample (Table 5). Compared with non-opioid uses, 
those prescribed opioids had higher medical expenditures across every category of 
medical spending. The sample mean of total annual medical expenditures were $23,413 
for the opioid group and $8,969 for non-opioid groups with $14,444 difference. Hospital 
inpatient stays, hospital outpatient visits and prescribed medicines were the three-major 
driven components for the expenditure difference. These differences were from PS 
matched samples, which adjusted to demographic or clinical characteristics that differ 
between opioid and non-opioid users.  
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Table 5 Comparison of Different Types of Medical Expenditures for PS-Matched 
CNCP sample. 
 Opioids 
(n=979) 
Non-Opioids 
(n=979) 
 
Variables $ Mean (S.D.) $ Mean (S.D.) $Difference 
Total Medical 
Expenditures* 
23,413 (43,057) 8,969 (27,185) 14,444 
Office Visits * 2,440 (4,368) 1,142 (3,466) 1,298 
Hospital Outpatient Visits * 3,833 (12,601) 1,304 (5,733) 2,529 
Ambulatory Visits* 418 (1,689) 200 (1,004) 218.7 
Hospital Inpatient Stays* 11,192 (37,066) 4,265 (23,788) 6,927 
ED Visits * 1,106 (3,506) 572 (3,434) 534.3 
Prescribed Medicines* 3,536 (7,315) 1,256 (3,190) 2,280 
Home Health Care 886 (5,864) 231 (1,888)         421  
*P-value<0.05 
 
 
2.4 Discussion and Limitations 
Based on the MEPS data, this analysis estimated the impact of opioid treatment 
on healthcare expenditure. The unadjusted yearly average total health expenditure was 
$23,413 higher for opioid group than non-opioid group. To further breakdown, the 
difference was mainly from hospitalizations, outpatient visits and prescriptions. 
Although, there had been no same model specification published yet, this estimation was 
consistent with other similar study (Kern et al., 2015).  In Kern et al.’s paper, they 
tracked CNCP patients’ health expenditure before and after the initiation of long-term 
opioid treatment. Their estimation were around $20,000 dollars increase after the 
initiation, which was close to my outcomes. Both Kern et al.’s study and this study 
found inpatient expenditure was the major cost driven factor for opioid treatment group. 
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There was no previous cross-sectional analysis that compared the overall annual 
health expenditure between long term opioid treatment group and non-opioid treatment 
group for CNCP patients. The finding showed huge difference for these two groups with 
PS matching for covariates. However, there were some limitations. First, the MEPs data 
is a self-reported database, which might have the subjective-bias problem. The 
participants of the survey might report incorrect information. However, the MEPs has 
been used in many studies and the quality of data has been validated. Moreover, to 
validate the findings, I used private insurance claims data to replicate this analysis in 
chapter 4.  
A second limitation is that the sample selection was based on the propensity 
score matching approach. The matching was on the known confounders, which might 
not include all the potential confounders, however we only could include all the 
variables that we had. And the after-matching sample, there was an adequate reduction 
of bias for many potential confounders, but overall the reduction in bias was not 
sufficient to assure the comparison was “apple-to-apples.”   
Last but not least, the comparison was at calendar year level, I did not investigate 
the expenditure at different timeframes, such as the comparison at 6-month after 
initiation of opioid treatment, 12-month, and 24-month.  And there was no comparison 
for CNCP patients’ health expenditure change before and after the opioid treatment. 
Next chapter was the longitudinal analysis for the expenditure comparison among CNCP 
patients before and after opioid and opioid treatment as well as the incremental cost 
associated with the diagnosis of CNCP condition.    
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2.5 Conclusion 
In the national opioid crisis, it would be informative to not only understand the 
effectiveness of the opioid treatment, but also the potential cost of treatment.  It is 
critical to investigate the health expenditure difference for opioid treatment when there 
has been lack of evidence to prove the long-term opioid treatments for CNCP as the best 
practice. This chapter investigated the health expenditure difference among CNCP 
patients with and without opioid treatment. By using MEPs data, I conducted the 
expenditure comparison for the PS matched sample. The outcomes showed the opioid 
treatment group had almost 3 times higher health expenditure compared to non-opioid 
treatment group. There were some limitations of this cross-sectional analysis, but the 
estimation was aligned with other studies. This huge health expenditure difference is 
mainly driven by inpatient and outpatient visits, as well as prescriptions.  
Although there are some limitations of this analysis, the outcomes gave policy 
makers, payers, physicians, and CNCP patients insights about potential expenditure 
difference with and without the opioid treatment. Different from other studies focused on 
certain types of chronic pain, this estimation was for all types of CNCP by using both 
ICD diagnosis code and SF-12 Questionnaire. Policy makers could use this estimation to 
assess the social cost for the opioid treatment and accordingly make change of the opioid 
management. Payers could use this outcome to adjust the reimbursement. Physicians 
could share this information with patients to help patient deciding on an appropriate 
CNCP management strategy.  My results underscore the high cost of opioid treatment to 
the health care system and highlight the need for cost-effective CNCP treatments.  
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CHAPTER 3. THE LONGITUDINAL ANALYSIS OF MEPS  
 
In the previous chapter, I used one-year MEPS data to compare the health 
expenditure for CNCP patients with and without long-term opioid treatments. The 
outcomes reveled great increase of health expenditure for long-term opioid treated 
patients. In order to confirm the difference was associated with opioid treatment rather 
than other health conditions or demographic factors, I adjusted the model by including 
covariates of gender, age, race, income, education, marital status, insurance types, and 
several health conditions. The final regression model showed that the health expenditure 
for opioid treatment group was 3 times higher than the non-opioid treatment group. Even 
though I did PS matching and multi-variable regression to avoid potential confounders, I 
only adjusted for known covariates. To further investigate the correlations between the 
higher health expenditure and the opioid treatment, I conducted a longitudinal analysis in 
this chapter. The strength of longitudinal study was to collect consistent data at a 
personal level, which excluded various background variables that could affect data 
outcomes.  
 
3.1 Introduction 
By using 10 years MEPs data, I took advantage of the panel data feature of 
MEPS to conduct the longitudinal study to explore the relationship between the opioid 
treatment and change of health expenditures. One study used the MEPS data did a 
longitudinal analysis to check the incremental cost for chronic pain condition (Henschke 
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et al., 2015). But no previous studies adopted longitudinal design to estimate annual 
health expenditure changes for initiation of new long-term opioid treatment on CNCP 
patients. There were two major research questions: 1) what was the change of annual 
health expenditures after new diagnosis of CNCP conditions? 2) what was the change of 
annual health expenditure for CNCP patients starting a new episode of opioid treatment?  
 
3.2 Data 
The data was from the calendar year 2000-2011 Household Component of the 
MEPS, which were HC-065 panel 5:2000-2001, HC-080 panel 7:2002-2003, HC-098 
panel 9:2004-2005, HC-114 panel 11:2006-2007, HC-130 panel 13:2008-2009, HC-148 
panel 15:2010-2011 (AHRQ, 2018).  MEPS sampled a new panel of households 
annually and tracked each panel for additional year. For each panel, MEPS gathered 
health and related expenditure information of everyone in the households during 5 
rounds interviews in the 2-year timeframe. All round 1 interview begun on February and 
ends on June of the first year, followed by round 2, which finished within 12-month 
period after the first interview. The round 3, 4 and 5 interviews were finished during the 
second year. So, for each panel, the final consolidated data included a full 2 years of 
records for each patient.  
I combined ten years MEPS longitudinal cohort to test the difference of 
expenditure for new developed CNCP patients before and after CNCP diagnosis, and the 
increase of medical expenditure caused by new opioid treatment for established CNCP 
patients. Since MEPS had two calendar years of data for each panel, it was possible to 
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identify the new diagnosed CNCP patients inside of each panel over 6 panels, as well as 
to track CNCP patients’ new episode of long-term opioid treatment.  
This study also used the MEPS Medical Conditions Files to capture household-
reported medical conditions. The medical conditions information was reported during 
the first year of the 2-year panel. I merged it into the longitudinal cohort. The final 
cohort exclude individuals younger than 18 years old by using the MEPS Self-
Administered Questionnaire (SAQ) eligible participates. The SAQ was part of the 
Household Component, which was given to all household respondents at least 18 years 
old during round 2 and round 4 (AHRQ, 2018).  
Among the adult patients, I excluded all the cancer patients, which were 
identified by ICD-9 diagnosis code and the health condition files same as the previous 
chapter.  Then, CNCP patients were flagged by ICD-9 diagnosis code and the answer of 
the SF-12 questioner same as the cross-sectional analysis to flag CNCP patients. 
 
3.3 Methods 
3.3.1 Measurements   
3.3.1.1 Dependent variables 
The dependent variable was the annual health care expenditure which included 
payments from third-party payers and self-out-of-pocket payments. The total health 
expenditure could be broken down by services types, where were inpatient expenditure, 
outpatient expenditure, prescriptions expenditure, emergency department visits 
expenditure, office visits expenditure and others (medical supplies and equipment, home 
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health care expenditure, dental, vision care expenditure and so on). The total expenditure 
was adjusted for inflation by the Consumer Price Index (CPI) to transfer to 2011 dollars 
(BLS, 2018 ). 
3.3.1.2 Predictor variables 
For the first research question: health expenditures after new diagnosis of CNCP 
conditions, the primary predictor variable was new diagnosis of CNCP conditions. The 
definition of new diagnosis was that patients did not have CNCP conditions in the first 
year and had CNCP conditions in the second year. The CNCP conditions were flag by 
both ICD-9 diagnosis code and survey questions, same as the previous chapter.  
For the second research question: the health expenditure for CNCP patients 
starting a new episode of long-term opioid treatment, the primary predictor variable was 
new episode of long-term opioid treatment, which was captured for CNCP patients that 
did not have opioid treatment in the first year and started long-term opioid treatment in 
the second year. The opioid treatment was flagged by the same NDC code as previous 
chapter. 
3.3.1.3 Model Covariates 
The longitudinal design of this chapter tracked the same cohort pre- and post-
CNCP diagnosis/ opioid treatment, to show the expenditure changes. The model 
excluded the difference for many characteristics at individual level. But at population 
level, there still could have other confounders influencing the relationships between 
predictor variables and expenditures. Other studies proposed some potential cofounders 
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for adjustment (Gaskin 2011, Richard 2012), which included demographic, social 
economics status, geographic location, and health conditions. 
In my model, I included age (continuous), gender (male and female), race (white, 
black, Hispanic, and other) and marital status (married or not) as the demographic 
covariates. For the socioeconomic covariates, I included education (high school or 
lower, and college or higher), household income level (poverty or not), insurance types 
(any private insurance, any public insurance, and uninsured). For the geographic 
variance, I included Metropolitan Statistical Area (MSA) yes or no.  For the health 
conditions, I included three types of covariates: health behaviors variables (smoking or 
not and physical activity or not), health status variables (excellent, very good, good, fair, 
and poor), and chronic condition variables (high blood pressure, heart disease, stroke, 
emphysema, chronic bronchitis, asthma, high cholesterol, diabetes, joint pain, and 
arthritis, as well as the body mass index (BMI). The health status variables were from 
self-reported health questioner SF-12. The answer for general health was used to reflect 
the health status. However, due to the pain related questions in the self-reported 
questioner were used in the CNCP flag, the covariates did not include them.  Since the 
chronic condition cancer had been used to distinguish CNCP patients, so the covariates 
did not include cancer as one of the chronic conditions. All the covariates were from the 
baseline (the first-year of the panel). 
3.3.2 Statistical Analysis 
The statistical analysis included descriptive analysis, bi-variates analysis, and 
regression models. I checked the sample’s baseline distribution of each measurement 
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and counted the incidence for developing new CNCP diagnosis and new opioid 
treatment. To show the correlation of new CNCP diagnosis and new opioid treatment 
episode with other factors, I conducted bivariate analysis over all covariates and total 
medical expenditure grouped by new CNCP and new opioid treatment from 2002 till 
2011 data. Differences between groups were assessed with χ2 or Fisher’s exact test for 
categorical variables, and Student t-test or Wilcoxon rank-sum test for continuous 
variables. 
Many studies used two-part model to estimate the medical expenditure, of which 
the first part was a logistic regression to estimate the likelihood of have non-zero 
expenditure and the second part was a regression model to assess the positive 
expenditure. For the second part regression models, GLM with gamma distribution and 
log-link function was a popular option. Some studies adopted quantile regressions to fit 
their data better. The model specifications were decided by the data availability and 
features. Still, there were some disadvantages of the two-part model approach. It was 
hard to simultaneously interpret the coefficients estimations from the logistic regression 
and the second part regression. Also, for the longitudinal data, it was difficult to detect 
the intra-class correlations among measurements from the same study object by the 
GLM or the quantile regressions.  
 I adopted generalized linear mixed models (GLMMs) to estimate the impact of 
new CNCP diagnosis and new opioid treatment (separately) on annual health 
expenditures for the same patient adjusted for all covariates. The model specification 
was: 
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𝑦𝑖𝑗 = 𝛽0𝑖𝑗 + 𝛽1𝑥1𝑖𝑗 +⋯+ 𝛽𝑧𝑥𝑧𝑖𝑗 
𝛽0𝑖𝑗 = 𝛽0 + 𝑢0𝑗  
𝑢0~𝑁(0, 𝜎𝑢
2
0
) 
𝑦𝑖𝑗  was the health expenditure for patient i at j time. The 𝛽 s at the first equation 
were fixed effects and 𝛽0𝑖𝑗 at the second equation was the random intercepts. The 𝜎𝑢0
2  
was the variance parameters to be estimated. 
Since the distribution of the health expenditures were right skewed with excess 
of zero values and a minority of high cost patients, the GLMMs handles zero-inflation 
and the gamma distribution fitted the data. By tolerating correlations within a subject via 
the hierarchical structure, this model could account for the overdispersion in the medical 
expenditure, which was caused by the excess zero values. In order to capture the 
distribution of the random residuals, a log-link function was adopted. Moreover, the 
GLMMs allowed both fixed and random effects treating patient-specific intercepts and 
linear change with time as random effects. This approach could assess the long-term 
opioid treatment (the key fixed effect) on the average change in total annual medical 
expenditure while accounting for the dependence of within-patient repeated measures 
over time.  
 The estimation calculated 95% confidence intervals, and the difference of 
expenditures were tested by non-parametric tests (will add citation later). All the 
analyses were performed using StataSE13 (Stata Corp, College Station, Texas, 2014) 
gllamm package (Generalized Linear Latent And Mixed Models) by maximum 
likelihood (Sophia Rabe-Hesketh & Anders Skrondal, 2012). 
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3.4 Results 
3.4.1 Cohort Selection Results 
By using the same method as the cross-sectional analysis, I identified a total of 
49,763 CNCP patients over 92,058 patients from 6 MEPS Longitudinal panels during 
2000-2011 period. The new developed patients were defined as no CNCP diagnosis at 
the first year of the panel data, but with CNCP diagnosis at the second year of the panel 
data. And 27,723 patients were identified as new developed CNCP patients.  Among the 
CNCP patients, there were 2,754 under opioid treatment, of which there were 1,072 
patients with the initiation of long-term opioid treatment. The data selection steps and 
results were shown in Figure 4: 
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Figure 4 2000-2012 Longitudinal MEPS Cohort Selection. 
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3.4.2 Descriptive Analysis Results 
3.4.2.1 New CNCP diagnosis as the major predictor variable 
The descriptive analyses result of new CNCP patients were shown in the table 5. 
By applying the MEPS longitudinal weight, the 27,723 observations in the sample 
represented 82,174,574 non-institutional population. The average age of the sample was 
49 years old, 51% were male, white individuals were the majority (65%), followed by 
16% Hispanic, 12% black and 7% other races. Currently married were 51% and 49% 
were currently single. 63% individuals had kept private insurance, 19% public insurance, 
4% uninsured, and 14% changing insurance status or unknown. Most of the individuals 
were in MSA (81%), 18% not in MSA, and 1% unknown.  For the health conditions, the 
tables showed the percent of people in each BMI category and health status category, as 
well as the rate of high blood pressure, heart disease, stroke, emphysema, bronchitis, 
asthma, high cholesterol, diabetes, and arthritis. 
 
Table 6 Descriptive Analysis of 2000-2011 New CNCP Sample. (n=27,723) 
Variables Mean Or %  S.D. 
Age 49 21 
Gender   
   Male 51% 0.2% 
   Female 49% 0.2% 
Race/ Ethnicity   
   White 65% 0.7% 
   Black 12% 0.4% 
   Hispanic 16% 0.6% 
   Other 7% 0.3% 
Marital Status   
    Current Married 49% 0.4% 
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Table 6 (continued)     
Variables Mean Or %  S.D. 
Insurance   
Keep Any Private Insurance 63% 0.50% 
Keep Any Public Insurance 19% 0.30% 
Keep Uninsured 11% 0.20% 
Private shift to Public 1% 0.10% 
Public shift to Private 1% 0.10% 
Unknown 5% 0.00% 
MSA   
Keep Yes 81% 0.20% 
Keep No 18% 0.20% 
Changed 1% 0.10% 
BMI   
Under weight 2% 0.00% 
Normal weight 37% 0.30% 
Overweight 35% 0.30% 
Obesity 26% 0.30% 
High Blood Pressure 15% 0.00% 
Heart Disease 3% 0.20% 
Stroke 2% 0.10% 
Emphysema 1% 0.00% 
Bronchitis 3% 3.00% 
Asthma 10% 0.20% 
High Cholesterol 25% 0.10% 
Diabetes 6% 0.10% 
Arthritis 11% 3.00% 
Health Status   
Excellent 22% 0.40% 
Very Good 41% 0.30% 
Good  29% 0.30% 
Fair 7% 0.10% 
Poor 1% 0.00% 
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There were 4% had zero health expenditure in the first year and reduced to 2% in 
the second year, which were statistically significant change (p=0.00). The average total 
annual health expenditure was $2,837 for the first year and $4,074 for the second year 
(p=0.00). 
 
Table 7 Expenditure Comparison for MEPS New CNCP longitudinal Sample. 
Variables Mean Or % zero expenditures Difference 
  
1st year  2nd year ∆Mean 
∆ of % 
$=0** 
Office Visits * $741 6% $926 4% $185 2% 
Hospital Outpatient Visits * $707 87% $1,412 83% $705 4% 
Ambulatory Visits* $111 81% $177 77% $66 4% 
Hospital Inpatient Stays* $1,258 95% $2,691 90% $1,433 5% 
ED Visits * $161 88% $176 81% $15 7% 
Prescribed Medicines* $608 37% $673 26% $65 11% 
Home Health Care $138 99% $144 98% $6 1% 
Total Medical Expenditures $2,837  4% $4,074  2% $1,237  2% 
*P-value<0.05 
**$=0 means zero expenditure        
 
3.4.2.2 New Opioid treatment as the major predictor variable 
The descriptive analyses result for patients started new opioid treatment were 
shown in the table 6. By applying the MEPS longitudinal weight, the 2,754 observations 
in the sample represented 4,881,281 non-institutional population. The average age of the 
sample was 50 years old, 41% were male, white individuals were the majority (75%), 
followed by 14% Hispanic, 8% black and 4% other races. Currently married were 51% 
and 49% were currently single. 56% individuals had kept private insurance, 33% public 
insurance, 4% uninsured, and 7% changing insurance status. Most of the individuals 
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were in MSA (84%).  For the health conditions, the tables showed the percent of people 
in each BMI category and health status category, as well as the rate of high blood 
pressure, heart disease, stroke, emphysema, bronchitis, asthma, high cholesterol, 
diabetes, and arthritis. 
 
Table 8 Descriptive Analysis of 2000-2011 New Opioid Treatment Sample. 
(n=2,754) 
Variables Mean Or %  S.D. 
Age 50 17 
Gender 41% 3.0% 
   Male 59% 0.1% 
   Female   
Race/ Ethnicity   
   White 75% 2.0% 
   Black 14% 2.0% 
   Hispanic 8% 1.0% 
   Other 4% 1.0% 
Marital Status   
    Current Married 51% 0.4% 
    Current Single 49% 3.0% 
Insurance   
Keep Any Private Insurance 56% 3.0% 
Keep Any Public Insurance 33% 3.0% 
Keep Uninsured 4% 2.0% 
Private shift to Public 4% 0.3% 
Public shift to Private 3% 1.0% 
MSA 84% 3.0% 
BMI   
Under weight 0.4% 2.0% 
Normal weight 27% 3.0% 
Overweight 32% 3.0% 
Obesity 41% 3.0% 
High Blood Pressure 15% 0.0% 
Heart Disease 5% 4.0% 
Stroke 4% 1.0% 
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Table 8 (continued) 
Variables Mean or % S.D. 
Emphysema 3% 2.0% 
Bronchitis 2% 2.0% 
Asthma 22% 3.0% 
High Cholesterol 40% 0.4% 
Diabetes 15% 0.2% 
Arthritis 49% 0.30% 
Health Status   
Excellent 7% 0.00% 
Very Good 28% 0.10% 
Good  29% 0.30% 
Fair 24% 0.30% 
Poor 11% 0.20% 
 
There were 4% had zero health expenditure in the first year and reduced to 0% in 
the second year, which were statistically significant change (p=0.00). The average total 
annual health expenditure was $7,970 for the first year and $13,569 for the second year 
(p=0.00).  
 
Table 9 Expenditure Comparison for MEPS New Opioid Treatment Sample. 
Variables Mean or % zero expenditures Difference 
  
1st year  2nd year ∆Mean 
∆ of % 
$=0 
Office Visits * $1,729 8% $2,722 5% $993 3% 
Hospital Outpatient Visits * $1,644 65% $5,820 57% $4,176 8% 
Ambulatory Visits* $202 63% $516 55% $314 8% 
Hospital Inpatient Stays* $1,258 86% $2,691 72% $1,433 14% 
ED Visits * $394 70% $421 61% $27 7% 
Prescribed Medicines* $1,861 7% $2,064 0% $203 7% 
Home Health Care $280 93% $144 92% $-136 1% 
Total Medical Expenditures $7,970  4% $13,569 0% $5,599 4% 
*P-value<0.05       
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3.4.3 Regression Model Results 
3.4.3.1 New CNCP diagnosis as the major predictor variable 
The GLMMs regression model results for new CNCP patients 2nd year health 
expenditures were shown in the table 10.  The mixed-effects regression showed the 
estimated health expenditure for new CNCP patients were $2,590 increase for the second 
year, after adjusted for demographic, SES, geographic, and health conditions. One-year 
age increase were associated with $80 increase of health expenditure increase. The 
individuals with private insurance $247 or with public insurance $430 had higher health 
expenditure than the people who uninsured or changing insurance status. MSA 
associated with $135 health expenditure increase. The high blood pressure ($359 higher) 
and heart disease ($239 higher) also related to higher health expenditure increase. 
Compared to excellent health status, other health status categories increase the health 
expenditure, which were shown in the table 10. The level 1 variance is 0.48 with 0.0001 
standard deviation.  
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  Table 10 GLMMs regression of Health Expenditure for New CNCP. 
Variables Coef. Std. Err. P>z [95%   C.I.] 
New CNCP* 2,590 155 0.00 2279 2901 
Age* 80 2 0.00 80 82 
Male 159 10 0.79 159 161 
White Ref 
 
 
  
Black -56 -4 0.39 -56 -54 
Hispanic* -183 -13 0.00 -183 -182 
Other -144 -16 0.12 -144 -143 
Current Married Ref 
 
 
  
Current Single 88 5 0.08 88 90 
Keep Any Private Insurance 534 150 0.00 533 536 
Keep Any Public Insurance* 430 112 0.01 429 432 
Private shift to Public 247 89 0.33 246 249 
Public shift to Private 518 249 0.09 517 520 
MSA* 135 11 0.03 135 137 
Under weight Ref 
 
 
  
Normal weight 175 39 0.37 175 176 
Overweight 231 46 0.23 231 232 
Obesity 207 43 0.29 207 208 
High Blood Pressure* 359 54 0.00 359 361 
Heart Disease* 239 22 0.00 239 241 
Stroke 159 19 0.06 159 161 
Emphysema 151 26 0.22 151 153 
Bronchitis 56 10 0.95 56 57 
Asthma 159 17 0.05 159 161 
High Cholesterol 56 4 0.31 56 58 
Diabetes* 391 43 0.00 391 394 
Arthritis* 143 11 0.01 143 145 
Health Status Excellent Ref 
 
 
  
Health Status Very Good* 454 104 0.00 454 456 
Health Status Good* 677 176 0.00 676 680 
Health Status Fair* 573 235 0.00 572 577 
Health Status Poor* 3,132 2161 0.00 3131 3138 
   *P-value<0.05 
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3.4.3.2 New Opioid treatment as the major predictor variable 
I also did the GLMMs model for the estimation of impact of new opioid 
treatment on health expenditures, which was reported in the table 11. The regression 
showed the estimated health expenditure for starting new opioid treatment patients were 
$5,468 increase for the second year, after adjusted for demographic, SES, geographic, 
and health conditions. One-year age increase were associated with $55 health 
expenditure increase. The individuals with private insurance ($476 higher) or with 
public insurance ($394 higher) had higher health expenditure than the people who 
uninsured or changing insurance status. MSA associated with $1,039 health expenditure. 
Compared to underweight, the normal weight was $2,078 less. The high blood pressure 
($3,251 higher), heart disease ($1,203 higher) and ($2,187 higher) also related to higher 
health expenditure increase. Compared to excellent health status, other health status 
categories increase the health expenditure, which were shown in the table 11. The level 1 
variance is 0.55 with 0.0002 standard deviation. 
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Table 11 GLMMs regression of Health Expenditure for New Opioid Treatment. 
Variables Coef. S.D. P>z [95%   C.I.] 
New Opioid*  5,468  2,078 0.01 1312 9,624 
Age*  55  0 0.00 55 57 
Male  109  8 0.68 109 111 
White  Ref  
 
 
  
Black  -164 -15 0.73 -164 -162 
Hispanic  820  66 0.08 820 822 
Other  437  70 0.60 437 439 
Current Married  Ref  
 
 
  
Current Single  273  19 0.52 273 275 
Keep Any Private Insurance*  476  171 0.00 475 478 
Keep Any Public Insurance*  394  138 0.00 393 396 
Private shift to Public*  328  171 0.07 327 330 
Public shift to Private*  1,531  1,608 0.00 1529 1,534 
MSA*  1,039  94 0.03 1039 1,041 
Under weight  Ref  
 
 
  
Normal weight*  -2,078 -416 0.14 -2078 -2,077 
Overweight  -2,679 -429 0.03 -2680 -2,679 
Obesity  -2,351 -423 0.08 -2352 -2,351 
High Blood Pressure*  3,281  558 0.01 3280 3,283 
Heart Disease*  1,203  120 0.02 1203 1,205 
Stroke  12  2 0.07 12 14 
Emphysema  1,094  208 0.27 1093 1,095 
Bronchitis  2,734  1,039 0.06 2733 2,736 
Asthma  711  78 0.21 711 713 
High Cholesterol  219 -15 0.62 -219 -217 
Diabetes*  2,187  262 0.00 2187 2,190 
Arthritis  492  39 0.24 492 494 
Health Status Excellent  Ref  
 
 
  
Health Status Very Good*  2,515  830 0.01 2515 2,518 
Health Status Good *  492  182 0.00 491 495 
Health Status Fair*  10,936  5,468 0.00 10935 10,939 
Health Status Poor*  16,404  12,139 0.00 16403 16,409 
  *P-value<0.05 
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3.5 Discussion and Limitations 
This chapter confirmed the assumptions of 1) new CNCP diagnosis associated 
with higher health expenditure, 2) starting new episode of opioid treatment increased 
health expenditure. The outcomes validated the estimations in cross-sectional analysis.   
Base on the 2000-2011 MEPS panel data, this chapter tracked the impact of new 
CNCP diagnosis and new opioid treatment on healthcare expenditure by the longitudinal 
model. The unadjusted average total expenditure increased $1,237 in 2nd year after new 
CNCP diagnosis and increased $5,599 in 2nd year after starting new opioid treatment. 
For adjusted estimations from the GLMMs models, mean yearly total health 
expenditure was $2,590 higher for new CNCP diagnosed patients compared to non-
CNCP diagnosis patients, and $5,468 higher for patients starting new opioid treatment 
after adjusted for demographic, SES, and health conditions. The GLMMs regression 
model combined covariates’ impact on expenditure with opioid treatment as the major 
predictor. Also, the model handled zero-inflation and skewness of the expenditure, as 
well as addressed the intra-class correlations among measurements from the same study 
object repeatedly at different time points. 
The results highlighted the economic burden caused by development of CNCP 
conditions, as well as the incremental cost of opioid treatment. Moreover, the estimation 
in this chapter align with other studies (Maeng et al., 2017; Smith et al., 2013). While the 
difference of per capital average annual total health expenditure before and after opioid 
treatment in longitudinal analysis was not as dramatic as the cross-sectional analysis 
results, it still increased the whole society’s economic burden and showed significant 
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cost for the whole health care system. The outcomes showed necessity to better manage 
CNCP condition in a more efficient and effective way. The stakeholders could use this 
estimation to evaluate alternative treatments and to make decision based on the cost and 
effectiveness. 
Even though the analysis gave insights about the health expenditure change 
associated with CNCP condition development, and initiation of new opioid treatment, it 
was important to understand the limitation of the analysis. One limitation was that the 
model was tracking the health expenditure change when new CNCP condition happened 
or new episode opioid started, which were consecutive events. But the model did not 
reveal the causal relationship between the independent variables and the dependent 
variable. Also, there were only two years record for each panel. The results could be 
more informative if the cohort could be tracked longer to check long-term impact on 
health expenditure. Another limitation was this study did not distinguish the level of pain 
in the model, which could give more insights of the major expenditure driven factors. 
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3.6 Conclusion 
This chapter found new CNCP conditions associated with $2,590 higher annual 
total health expenditure, and the initiation of new episode of long-term opioid treatment 
increased $5,468 higher annual total health expenditure. This pattern was consistent with 
cross-sectional analysis results. By applying the longitudinal weight, the results showed 
national level impact of the high cost of CNCP conditions and opioid treatment, which 
emphasized the need for more cost-effective management for CNCP patients. 
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CHAPTER 4. BLUE CROSS/BLUE SHIELD OF TEXAS ANALYSIS 
 
4.1 Introduction 
As noted previously, the MEPS data provided many advantages for analyzing the 
research questions addressed in this study, but the MEPS data also had potentially 
important limitations, mainly related to self-reporting of key variables by survey 
respondents. To determine if the results from the MEPS data were substantially affected 
by these limitations, I replicated the previously reported MEPS analyses using claims 
data from Blue Cross/Blue Shield of Texas (BCBSTX).  
The analysis in this chapter included: cross-sectional model to estimate the 
difference in health expenditures and adverse events (ER visits) between CNCP long-
term opioid treatment group vs. CNCP non-opioid treatment group; longitudinal models 
to compare the health expenditure before and after CNCP diagnosis and to track the 
health expenditure change after initiation of the long-term opioid treatment for CNCP 
patients. There were three major research questions in the longitudinal part: 1) Are there 
any changes in medical expenditures and/or specific types of medical resources use (e.g., 
ED visits) associated with the onset of CNCP; and 2) How much change in total medical 
spending and/or specific types of medical resources use do we see after initiation of 
long-term opioid treatment for CNCP patients, as compared to non-opioid CNCP 
patients. 3) How much change in total medical spending and/or specific types of medical 
resources use do we see after new diagnosis of CNCP, as compared to before diagnosis 
of CNCP conditions.  The model specifications were similar to the previous chapters, 
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which included cross-sectional mass-univariates analysis, the GLM regressions, and the 
longitudinal regression models. Due to the limitation of data, those models only adjusted 
for the basic demographic information, which are age and gender. The data were from 
CY2008-CY2012 BCBSTX. 
 
4.2 Data 
Unlike the self-reported data in MEPS, the BCBSTX claims provided an option 
to completely capture all medical care services with claims processed by BCBSTX. 
There were several benefits of using the BCBSTX claims data for the study aims. First, 
the large number of claim records would provide an adequate sample to estimate the 
prevalent or incident of CNCP conditions. Also, the dataset included 5 years’ BCBSTX 
claims, which enabled the longitudinal analysis. Second, the BCBSTX medical claims 
data contained the ICD-9 diagnosis codes and HCPCS/CPT codes which were needed to 
identify specific individuals in the database meeting the case-finding definitions for 
CNCP conditions, and the pharmacy claims contained National Drug Code (NDC) codes 
which were needed to identify all the long-term opioid treatment.  Finally, the BCBCTX 
database included expenditure (payment) information, which was necessary to estimate 
the incremental expenses associated with incident CNCP conditions and differences in 
medical costs between opioid and non-opioid treatment groups. While some medical 
care use may be missed using claims data, these errors generally have a limited impact 
on measurement of total medical care expenditures (Wolinsky et al. 2007).   
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The cross-sectional analysis compared the expenditure difference for CNCP 
patients between the opioid treatment group and non-opioid treatment group. This 
analysis used calendar year 2011 claims data to match the MEPS cross-sectional 
analysis, with the sample of CNCP patients selected based on the presence of claims 
history during 2011 consistent with the case-finding definitions for CNCP conditions 
used in the study. The claims include both professional and facility claims.  
The longitudinal analysis focused on the change in medical expenditures 
associated with the onset of CNCP and the initiation of new opioid treatment, I also used 
all claims data   (professional and facility claims) for CY2008 through CY2012   to 
identify new cases of CNCP for CY2009 and each calendar year thereafter (defined as 
the presence of diagnosis codes identifying CNCP following at least 1 year of claims 
without CNCP codes).  Once the date of onset of new CNCP is established for each 
patient, for each new CNCP patient I calculated total medical expenditures (and specific 
resource use counts) for 1 year prior to the patient's CNCP onset date and for at least 1-
year post-CNCP onset, which was up to 3 years of follow-up.   
The study used a similar approach to identify new episodes of long-term opioid 
use in the data. A new episode of long-term opioid treatment was defined as beginning 
on the first date of an opioid prescription for a CNCP patient (after CNCP onset date), 
following a period of at least 6 months without any opioid prescriptions, resulting in at 
least 90 days supplied for one or more opioids over a subsequent 180-day period. The 
study restricted the final sample of CNCP patients employed in the longitudinal analysis 
 71 
 
to patients with continuous eligibility over both calendar years (2008-2009, 2009-2010, 
2010-2011, 2011-2012).   
 
4.3 Methods 
The analyses included three parts: 1) descriptive analysis, 2) cross-sectional 
analysis, 3) longitudinal analysis. For the descriptive analyses, I described the basic 
features of the CNCP sample by providing summaries about the sample and the 
measures. I then used univariate analysis to estimate the demographic and clinical 
characteristics of participants as proportions for categorical variables and means with 
standard deviations (SD) for continuous variables. Finally, I did a histogram chart to 
show the distribution of the health expenditures for CNCP patients with and without 
long-term opioid treatment at 2011.   
4.3.1 Method for the Cross-Sectional Analysis   
To address hypothesis 1 that the opioid treatment group will have higher total 
medical expenditures than non-opioid patient, total medical expenditures are measured 
by the summing the variable "total paid amount” over a given year.  By using the drug 
claim file, I flagged the opioid treatment patients if they had filled opioid prescriptions 
list which included 13,270 drugs (NIDA, 2018) in appendix 1. The filled prescription 
was defined as non-zero payment and unit. To test for differences in expenditures 
between the opioid and non-opioid treated CNCP groups, I used a t-test and define 
statistical significance at the 5 percent significance level.  
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To estimate overall expenditures for the CNCP patients with and without opioid 
treatment when adjusted for demographic and socioeconomic status, I adopted a linear 
regression and a log-link Gamma regression model using patient-level characteristics as 
covariates. Similarly, I used a logistic or count-based regression model to assess the 
impact of opioid or non-opioid pain treatment on ED use among patients with CNCP.  
For hypothesis 2, which supposed the opioid treatment group would have more 
ER visits than non-opioid patients, I defined the ER visit by Current Procedural 
Terminology (CPT) / Healthcare Common Procedure Coding System (HCPCS) Code in 
the range of “99281" to "99285", as well as the Revenue code 
"0450","0451","0452","0456","0459" and "0981  ". I conducted a t-test to show the 
unadjusted difference of the average of total count of ER visits between the opioid and 
non-opioid group. I also performed a logistic regression, using ER (Yes=1, No=0) as the 
outcome variable and opioid treatment as the predicted variable, and adjusted for patient-
level demographic and (geo-coded proxy measures of) socioeconomic characteristics to 
show the odds ratio of ER events for the opioid and non-opioid group.     
For the cross-sectional analysis, the annual overall medical expenditures across 
CNCP and non-CNCP groups at baseline were compared using linear regression models 
including long-term opioid treatment as the independent variable and annual total paid 
medical expenditures as a dependent variable adjusting for sociodemographic variables. 
The construction of the regression models depends also upon the availability of data. 
The model specification for general linear repeated measure models (GLM) with log link 
is  
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𝐸[𝑦|𝑥] = 𝑓(𝑥′𝛽) = exp(𝑥′𝛽) 𝐼𝑛(𝐸[𝑦|𝑥]) = 𝑥′𝛽 
and gamma distribution  
𝑦~𝑉𝑎𝑟(𝑦|𝑥) ≈ (𝐸[𝑦│𝑥])𝜆 
to test the differences in medical expenditures across CNCP and non-CNCP groups at 
2011, This model connected the linear predictor and the mean of the distribution 
function by allowing dependent variables had arbitrary error distribution, which fitted 
CNCP sample better than the ordinary linear regression (OLS) model (Nelder 
JWedderburn, 1972). The GLM estimator with gamma distribution and a log-link 
function relaxed the assumption that the error distribution must follow a normal 
distribution and solved heteroskedasticity issues. I conduced several diagnostic tests for 
modeling fitting. I used modified Park test for the GLM family. To be more specific, the 
Gamma distribution suited to dealing with heteroskedasticity in non-negative data. 
Manning and Mullahy recommended a modified Park test to confirm the choice of 
distribution family of the regression mode as the correct specification among different 
GLMs (Manning & Mullahy, 2001). The Pearson correlation test was for checking 
systematic bias in fit on raw scale. After regression, Hosmer-Lemeshow tests were 
performed to check if the link functions fit the data well, which tested first divide the 
observations into 10 identical sized clusters based on predicted values, and then use F-
test to check if the mean residuals are equal among the 10 clusters. If null hypothesis 
was not rejected, the model shows goodness-of-fit (Hosmer & Lemeshow, 2000). And 
the Pregibon link test checked linearity of response on scale of estimation.  
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4.3.2 Method for the Longitudinal Analysis   
To answer the research questions, the longitudinal analysis addressed the 
following hypotheses: H1) the onset of new CNCP diagnosis would increase total 
medical expenditures, and H2) among CNCP patients the initiation of a new episode of 
long-term opioid prescription use will increase total medical expenses for CNCP 
patients. To test the hypotheses, I adopted the GLMMs model, which allowed both fixed 
and random effects treating patient-specific intercepts and linear change with time as 
random effects. This approach allowed me to assess the new CNCP diagnosis or the new 
episode of long-term opioid treatment (the key fixed effects) on the average change in 
total annual medical expenditure while accounting for the dependence of within-patient 
repeated measures over time. The model specification was: 
𝑦𝑖𝑗 = 𝛽0𝑖𝑗 + 𝛽1𝑥1𝑖𝑗 +⋯+ 𝛽𝑧𝑥𝑧𝑖𝑗 
𝛽0𝑖𝑗 = 𝛽0 + 𝑢0𝑗  
𝑢0~𝑁(0, 𝜎𝑢
2
0
) 
The 𝑦𝑖𝑗  was the health expenditure for patient i at j time.  
The 𝛽 s at the first equation were fixed effects and 𝛽0𝑖𝑗 at the second equation 
was the random intercepts.  
The 𝜎𝑢0
2  was the variance petameters to be estimated.  
Since the distribution of the health expenditures were right skewed with excess 
of zero values and a minority of high cost patients, the GLMMs handles zero-inflation 
and the gamma distribution fitted the data.  
 75 
 
By tolerating correlations within a subject via the hierarchical structure, this 
model could account for the overdispersion in the medical expenditure, which was 
caused by the excess zero values. In order to capture the distribution of the random 
residuals, a log-link function was adopted. Moreover, the GLMMs allowed both fixed 
and random effects treating patient-specific intercepts and linear change with time as 
random effects. This approach could assess the long-term opioid treatment (the key fixed 
effect) on the average change in total annual medical expenditure while accounting for 
the dependence of within-patient repeated measures over time.  
Since there were not many covariates in the BCBSTX data, the GLMMs models 
only included age (continuous), sex (male and female), race (white, black, Hispanic and 
other), marital status (married or not), income (average household income by ZIP Code), 
Charlson comorbidity index (no comorbidity, low comorbidity, and high comorbidity), 
and initiation of new-opioid treatment or new-diagnosis of CNCP.  
The estimation calculated 95% confidence intervals, and the difference of 
expenditures were tested by non-parametric tests. All the analyses were performed using 
StataSE13 (Stata Corp, College Station, Texas, 2014) gllamm package (Generalized 
Linear Latent and Mixed Models) by maximum likelihood (Rabe-Hesketh & Skrondal, 
2012). 
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4.4 Results 
4.4.1 Results for the Cross-Sectional Analysis   
There were 2,623,290 unique patients from 2008 to 2012 in BCBSTX. By 
applying the CNCP flag, I identified 498,800 patients with CNCP conditions in 2011, 
and 14% of those patients had long term opioid treatment. The yearly prevalence for 
CNCP patients counts and patients with long opioid treatment are shown in table 10. The 
yearly CNCP was increasing from 2008 to 2012 in both absolute count and percent over 
overall patients. The number of CNCP patients with opioid treatment grew from 2008-
2012, but the rate of patients under opioid treatment over all CNCP patients remained 
consistent (14%) during those years. 
 
Table 12 Sample size for BCBSTX Cross-Sectional Analysis. 
Year All unique patients 
CNCP 
Patients 
CNCP with Long-term 
Opioid patients 
2008 1,629,367 369,723 22% 48,818 13% 
2009 1,763,210 419,877 24% 58,296 14% 
2010 1,835,525 457,696 25% 66,265 14% 
2011 1,882,601 498,800 26% 68,419 14% 
2012 1,814,814 493,513 27% 70,321 14% 
 
In the cross-sectional part, the descriptive analysis showed the percent or mean of 
each covariate, dependent and independent variable for 2011 CNCP sample. Among all 
the CNCP patients, 14% received long-term opioid treatment. Males were only 37% of 
the CNCP sample. The average age was 47. The annual average total health expenditure 
was $6,650. 
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Table 13 Descriptive Results for 2011 BCBSTX Cross-sectional Analysis. 
Variables 
Opioid Treated 
CNCP Patients 
(n=68,419) 
Non-Opioid Treated 
CNCP Patients 
(n=430,381) 
Overall 
CNCP Patients 
(n=498,800) 
n % n % n % 
Charlson Comorbidity 
Index  
     
  0: no comorbidity 41,023 60% 296,677 69% 337,700 68% 
  1: low comorbidity 17,692 26% 91,433 21% 109,125 22% 
  2: high comorbidity 9,704 14% 42,271 10% 51,975 10% 
Male 27,935 41% 157,769 37% 185,704 37% 
      
 Mean S. D. Mean S. D. Mean S. D. 
Age 47 12 47 14 47 14 
Income (Median 
income of each zip) 
59,843 23,786 59,919 24,803 59,909 24,666 
Total Annual Payment 14,582 35,014 5,389 20,327 6,650 23,044 
 
To show the distribution of annual health care expenditure, I created two 
histogram charts: one is for all the CNCP patients’ expenditure (figure 5), and the other 
one included up to the 95 percentiles expenditures (figure 6). The reason of having two 
charts was the long right-hand tail of the expenditure, which represent some outlies over 
one million dollars. In the figure 5 and 6, the annual total health care expenditure was 
left side skewed and the majority (>50%) CNCP patients had less than $10,000 annual 
health expenditure.  
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Figure 5 Histogram for 2011 All CNCP Patients Annual Healthcare Expenditure. 
 
 
 
Figure 6 Histogram for 2011 CNCP Patients Annual Healthcare 95 Percentiles 
Expenditure. 
 
 
I ran OLS and GLM regression models for the cross-sectional analysis; table 14 
showed the impact of opioid treatment on annual total health expenditure after adjusting 
for the demographic covariates. According to the coefficient’s estimations, the opioid 
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Figure 6: Histogram for 2011 CNCP Patients Annual Total Payment
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treatment group had $21,681 higher health expenditure than non-opioid treatment in the 
OLS model, and 2.65 times higher in GLM model after adjusting for gender and age.   
 
Table 14 Regression results for cross-sectional analysis for 2011 BCBSTX. 
Variables 
OLS GLM 
Coef P-value 95% C.I. Exp (Coef) P-value 95% C.I. 
Opioid 8,103 0.00 [7,923, 8,283] 2.60 0.00 [2.54, 2.65] 
Male 167 0.00 [39, 295] 1.02 0.00 [1.00, 1.04] 
Age -19 0.00 [-24, -14] 1.00 0.00 [1.00, 1.00] 
Comorbidity Reference group Comorbidity index is 0 
  Low 3,933 0.00 [3,778, 4088] 2.09 0.00 [2.05, 2.13] 
  High 20,907 0.00 [20,692, 21,122] 6.64 0.00 [6.48, 6.81] 
Income .02 0.00 [.01, .02] 1.00 0.00 [1.00, 1.00] 
Cons 4472 0.00 [2,114, 2,662] 8.4 0.00 [8.37, 8.43] 
 
4.4.2 Results for the Longitudinal Analysis 
For the longitudinal analysis sample, the final cohort count was reported in the 
table 16. Around 62% patients had 2-years continuous enrollment and 28% of those 
patients had CNCP conditions in both years. The new diagnosed CNCP conditions were 
around 22% of 2-years continuous enrolled patients. The initiation of new opioid episode 
was around 2% among patients with CNCP conditions in both years.  
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Table 15 Sample Selection for BCBSTX Data. 
Year Continuously 
enrolled 2 
years 
CNCP in 
both years 
New diagnosed 
CNCP 
CNCP patient 
initiation of 
new opioid 
episode 
# # # % * # % ** 
2008-2009 741,520 137,828 166,198 22% 3,321 2% 
2009-2010 824,641 164,445 176,323 21% 3,979 2% 
2010-2011 874,588 182,611 188,261 22% 4,209 2% 
2011-2012 866,774 186,475 184,669 21% 4,432 2% 
* Denominator:  two-year continuously enrolled patients 
** Denominator: CNCP in both years 
 
The descriptive analysis for new diagnosis of CNCP conditions (table 17) 
showed a statistically significant difference in annual health expenditure change, gender, 
comorbidity and age between new diagnosed CNCP group and non-new diagnosed 
CNCP group. The new CNCP group was slightly older, and female with higher Charlson 
comorbidity score.   There was $ 6,542 expenditure increase for the new CNCP group 
and $509 decrease for non-new CNCP. 
 
 
 
 
 
 
 
 
 81 
 
Table 16 Descriptive Analysis of New Diagnosed CNCP. 
Variables 
  
New CNCP 
(n=715,451) 
Non-new CNCP*  
(n=5,459,586) 
Overall 
(n=6,175,037) 
n % n % n % 
Male* 262,195 37% 2,148,692 39% 2,410,887 39% 
Comorbidity*       
 0 no comorbidity 372,586 69% 2,689,692 74% 3,062,278 73% 
 1 low comorbidity 113,437 21% 648,647 18% 762,084 18% 
 2 high comorbidity 53,105 10% 298,520 8% 10% 9% 
       
  Mean S.D. Mean S.D. Mean S.D. 
Age* 46 13.59 45 13.72 46 13.71 
Income (by zip) 59,725 29.52 59,630 10.64 59,641 10.01 
Difference of 
Expenditures* 6,542 26.51 -509 12.58 
 
308 
 
11.43 
* (Prob>F) <0.05 
**Non-new CNCP group include patients no CNCP conditions in both years, CNCP conditions in both years, with 
CNCP in the first year and no CNCP in the second years 
 
The descriptive analysis for CNCP patients with new opioid episode (table 18) 
showed a statistically significant difference of gender, age, and Charlson comorbidity 
score. The new opioid treatment patients were more like to be males, higher comorbidity 
scores, and slightly younger age. There was $7,841 increase of annual health expenditure 
for new opioid group. The increase of annual health expenditure was $7,679 higher for 
the new opioid group than the non-new opioid group. 
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Table 17 Descriptive Analysis of CNCP Patients Starting New Episode of Opioid 
Treatment. 
Variables 
  
New Opioid 
(n=15,941) 
Non-new opioid 
(n=655,418) 
Overall** 
(n=671,359)  
n % n % n % 
Male* 5,658 35% 219,308 33% 224,966 34% 
Comorbidity*       
 0 no comorbidity 6,698 56% 301,380 61% 308,078 61% 
 1 low comorbidity 3,432 29% 126,420 26% 129,852 26% 
 2 high comorbidity 1,832 15% 67,152 14% 68,984 14% 
       
  Mean S.D. Mean S.D. Mean S.D. 
Age* 49 13 50 14 50 14 
Income (by zip) 58,994 191 58,896 30 58,898 30 
Difference of 
Expenditures* 7,841 292 162 35 
 
344 
 
35 
*: (Prob>F) <0.05  
**All the patients were CNCP patients who had two-years continuous CNCP conditions 
 
The GLMMs regression model estimated the change of medical expenditures for 
new developed CNCP patients.  For the goodness of fit, the R^2 between was 0.15. If 
using these estimates to predict the within model, the R^2 was 0.08. If using these 
estimates to fit the overall data, the R^2 was 0.11. The F statistic tests that all 
coefficients on the regressors are jointly zero, and this model was significant 
(Prob>F=0.00). The level 1 variance is 0.46 (S.D. 0.0001). After adjusting for gender, 
age, comorbidity, income, new diagnosis of CNCP conditions was associated with 
$2,567 more increase of annual medical expenditures than non-new diagnosed CNCP 
patients. This study also used a GLMMs regression model to estimate the annual 
medical expenditures for established CNCP patients with initiation of a new episode of 
long-term opioid treatment.   
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For the goodness of fit, the R^2 between was 0.15. If using these estimates to 
predict the within model, the R^2 was 0.05. If using these estimates to fit the overall 
data, the R^2 was 0.12. The F statistic tested that all coefficients on the regressors are 
jointly zero, and this model was significant (Prob>F=0.00). I also did the Hausman 
random effects tests and the results showed there were no random effects. After 
adjusting for gender, age, and age interaction, initiation of new opioid treatment was 
associated with $6,625 increase of total average annual medical expenditures than non-
new opioid treatment CNCP patients. Male was omitted due to the collinearity since it 
did not vary within person.  
 
Table 18 GLMMs Results for Newly CNCP Diagnosis Patients and New Start of the 
Opioid Episode. 
Variables New CNCP Model New Opioid Model 
 Coef. P-value 95% C.I. Coef. P-value 95% C.I. 
New CNCP 2,567 0.00 [2,305, 2,413]    
New Opioid    6,625 0.00 [5,409, 6,890] 
Male 
408 0.03 
[-1,707, 
2,522] 
-1,507 0.81 
[-13,919, 
10,906] 
Age 49 0.03 [5, 94] -381 0.04 [-752, -10] 
Comorbidity 
 0 no  
 1 low  
 2 high 
 
Ref 
3,701 
15,11
0 
 
 
0.00 
0.00 
 
 
[3,634, 3,767] 
[15,003, 
15,219] 
 
Ref 
4,486 
14,396 
 
 
0.00 
0.00 
 
 
[4,157, 4,815] 
[13,903, 
14,889] 
Income  
(by zip) 
0.00 0.94 
[-0.003, 
0.003] 
-0.01 0.26 [-0.03, 0.01] 
Cons 
-258 0.71 
[-1,623, 
1,107] 
22,872 0.00 
[11,910, 
33,833] 
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4.4.3 Results for the Emergency Department Visits  
For the emergency department visits, there were 24% patients had ED visit 
yearly for the long-term opioid CNCP group, and 15% for the non-opioid group. The 
opioid group is 9% higher than the non-opioid group (Pr>t=0.00). For the patients with 
ED, the average yearly total ED visit count for long-term opioid CNCP patients were 3 
and for non-opioid treatment were 2 (Pr>t=0.00). 
The study also compared the count change (increase or decrease) of yearly ED 
visits before and after the new CNCP diagnosis. There was 0.28 increase for patients 
with new CNCP diagnosis and 0.07 decrease for patients who did not have new CNCP 
diagnosis (Pr>t=0.00).  
In addition, the study also checked the count difference of yearly ED visits 
before and after the initiation of new opioid episode. There was 0.28 increase for 
patients started new long-term opioid treatment and 0.02 decrease for patients did not 
have long-term opioid treatment (Pr>t=0.00). 
 
4.5 Discussion and Limitations 
Base on the five-year BCBSTX data, this chapter tested same hypotheses as the 
MEPS analysis to estimate the impact of opioid treatment on healthcare expenditure. 
Both the cross-sectional and the longitudinal models showed significant higher cost for 
the opioid treatment than the non-opioid treatment CNCP patient group. In the cross-
sectional analysis, the adjusted mean of 2011 annual health expenditure was $8,103 
higher for opioid group than non-opioid group in the OLS model. I also adopted the 
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GLM repeated measure regression model with gamma distribution to better fit the skew 
of expenditure data. Combined covariates’ impact on expenditure with opioid treatment 
as the major predictor, the GLM repeated measure model showed the opioid group had 
2.65 times of annual expenditure compared to non-opioid treatment group, which was 
close to MEPS estimation. The MEPS estimated mean health expenditure was 3 times 
higher for the opioid treatment group compared to non-opioid treatment group after 
matching for demographic, SES, and health conditions.  
 The longitudinal FE model showed the initiation of new opioid episode was 
$6,625 more increase than the non-new opioid episode after adjusting for age, gender, 
comorbidity and income. The difference of expenditure change was relatively smaller 
between new diagnosis of CNCP conditions and non-new CNCP conditions, which were 
$2,567. This estimation reveled the CNCP condition did not drive health expenditure as 
much as the new initiations of opioid treatment. The opioid treatment was the major 
factor associated with the higher health expenditure. 
I also compared the count of ER visits for opioid treatment and non-opioid 
treatment group to better understand the difference of health utilization and adverse 
events associated with opioid treatment. The outcome showed statistically significant 
higher ER visits for opioid treatment group. Also, there was increase of ER visits after 
the new CNCP treatment or the initiation of new opioid treatment. 
All the model showed goodness of fit. The results were consistent with MEPS 
outcomes and other studies’ estimations. The longitudinal analysis eliminated various 
background variables that could affect data outcomes and the outcomes were robust. 
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4.5.1 Limitation 
There was no previous analysis that used both national survey data and private 
insurance claims data to compare the overall annual health expenditures between long 
term opioid treatment group and non-opioid treatment group for CNCP patients. The 
finding showed similar difference for these two groups in either cross-sectional or 
longitudinal models. However, there were some limitations. First, the BCBTX data was 
insurance claims administration data, which only captured the claims activities and basic 
demographic information. There was limited social economic status variables about their 
members, as well as no self-reported health outcomes. In order to adjust for 
comprehensive potential cofounders, I linked the members’ residential ZIP Code to 
censor data to get the median income. Also, I calculated the Charlson Comorbidity score 
to capture the health status of each member.  Even though the covariates adjustment was 
not as inclusive as the MEPS analysis, the BCBSTX analysis already adjusted for all the 
possible covariates. The consistent estimation across different models showed the 
robustness of the estimations.   
Another limitation was BCBSTX data only compared the total health 
expenditure. The MEPS analysis did compare the health expenditure in several different 
services’ bucket, such as ER, inpatient, outpatients, office visits and so on. The data 
structure was different and the BCBSTX data did not have the variable or grouper to 
distinguish the expenditure for different services bucked. Although the outcomes showed 
the opioid treatment related to much higher health expenditure than the new CNCP 
diagnosis, it did not deep dive where those differences came from: were they caused by 
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adverse-effect of opioid treatment or were the utilization of a specific service bucket 
systematically different for opioid and non-opioid patients. But the comparison of using 
ER visits in BCBSTX analysis gave some clues that there were increase of adverse 
events which might contributed to the rise of the expenditure. 
Additionally, this analysis only used Texas data, which might have some regional 
bias. But the outcomes were close to the national MEPS data, which proved the Texas 
data were sufficient. 
4.5.2 Conclusion  
This chapter replicated the MEPS cross-sectional and the longitudinal analysis in 
the five-year BCBSTX claims data. The estimation aligned with the MEPS outcomes, 
which showed the around 3 times higher health expenditure for CNCP patients with 
opioid treatment than without opioid treatment.  
Although there are some limitations of this analysis, the outcomes give 
policymakers, payers, physicians, and CNCP patients insights about potential 
expenditure difference with and without the opioid treatment. Different from other one 
data sources study, this study analyzed both private insurance claims data and national 
survey data, which enhanced the validity and reliability of the outcomes. 
Policymakers could use this estimation to assess the social cost for the opioid 
treatment and accordingly make change of the opioid management. Payers could use this 
outcome to adjust the reimbursement. Physicians could share this information with 
patients to help patient deciding on an appropriate CNCP management strategy.  My 
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results underscore the high cost of opioid treatment to the health care system and 
highlight the need for cost-effective CNCP treatments. 
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CHAPTER 5. CONCLUSION 
 
This study investigated the annual health expenditure difference between long-
term opioid treated CNCP patients and non-opioid treatment CNCP patients in cross-
sectional analyses controlling for demographic, SES and clinical characteristics. The 
study also compared the change of medical expenditures associated with the 
development of new CNCP condition and the initiation of new long-term opioid 
treatment episode. The analysis based on two types of data: self-reported national survey 
panel data (MEPS) and regional private insurance administration (Texas Blue Cross 
Blue Shield) claims data. The outcomes had been cross-validated from different data 
sources and different research designs (cross-sectional setting and the longitudinal 
setting). The findings demonstrated the hypotheses that CNCP condition and new opioid 
treatment were statistical significantly associated with higher total medical expenditure 
with and without risk adjustment across different data and models. Additionally, the 
emergency department visits were higher for CNCP patients and patients under opioid 
treatment. 
 
5.1 Results 
To be more specific, the estimation results from different data and different 
models were summarized in table 19, which showed the opioid related health 
expenditure difference (cross-sectional) or change (longitudinal). In the cross-sectional 
analysis, the difference of annual health expenditure was $23,413 for MEPS and was 
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$9,193 for BCBSTX in the descriptive analysis, and after adjusted for demographic, 
SES, comorbidity and health status, the OLS model showed opioid group was $8,103 
higher than non-opioid group in BCBSTX model. And the GLM repeated measure 
models showed the opioid group annual health expenditure was 2.65 times than the non-
opioid treatment group for BCBSTX sample.   
For the longitudinal setting, the descriptive analysis for the difference of annual 
health expenditure increase of new-opioid episode group was $5,599 for the MEPS data 
and $7,679 for the BCBSTX data. The GLMMs model showed MEPS had $5,468 
increase for opioid treatment group than the non-opioid treatment group, and the 
BCBSTX assessed the increase of the health expenditure for new-opioid group was 
$6,625 higher than the non-new opioid group, after adjusted for all the covariates. 
 
Table 19 Opioid Treatment Related Health Expenditure Comparisons in Cross-
sectional and Longitudinal settings. 
  Data Source  MEPS BCBSTX 
Cross-sectional     
 ∆ of annual health expenditure* $23,413  $ 9,193  
 OLS  N/A   $ 8,103  
 GLM N/A 2.65 times 
Longitudinal    
 
∆ of annual health expenditure 
increase $5,599  $7,679  
  GLMMs  $5,468  $ 6,625 
*Cross-sectional MEPS part did the comparison after PS matching and no regression, and the BCBSTX did 
multivariate regressions and not PS matching. 
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Both data sets showed long-term opioid treatment had higher health expenditure 
or larger increase. The approach to calculate the MEPS annual health expenditure 
included all types of health expenditure, and the BCBSTX only included claims 
payment. Since the BCBSTX total expenditure was not as comprehensive as the 
MEPS’s, the BCBSTX estimations was lower than the MEPS. But all the difference or 
changes were in the same direction and the GLM times estimation were very similar. 
In the longitudinal analysis for both datasets, the study also explored the 
difference of annual health expenditure change between new-CNCP diagnosis group and 
non-new CNCP diagnosis group. The difference was $1,237 increase for MEPS and was 
$7,051 more increase for BCBSTX in the descriptive analysis. After adjusted for 
demographic, SES, comorbidity and comorbidity and health status, the MEPS GLMMs 
model showed the new-CNCP group annual health expenditure was $2,590 increase than 
the non-new CNCP group. The BCBSTX CLMMS model assessed the increase of the 
health expenditure for new-CNCP group was $2,567 higher than the non-new CNCP 
group, after adjusted for all the covariates. 
For the emergency department visits, the MEPS data compared annual ER 
expenditure difference and change. The MEPS cross-sectional results showed the opioid 
group annual ER expenditure was $911 higher than then non-opioid group. The MEPS 
longitudinal results showed the new-opioid group was $27 higher increase of annual ER 
expenditure than the non-new opioid group, and the new CNCP group was $15 higher 
than the non-new CNCP group.  
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The BCBSTX data compared the difference and change of the annual ER visits 
count. There were 24% patients had ED visit yearly for the long-term opioid CNCP 
group, and 15% for the non-opioid group. The opioid group is 9% higher than the non-
opioid group (Pr>t=0.00). For the patients with ED, the average yearly total ED visit 
count for long-term opioid CNCP patients were 3 and for non-opioid treatment were 2 
(Pr>t=0.00). The study also compared the count change (increase or decrease) of yearly 
ED visits before and after the new CNCP diagnosis. There was 0.28 increase for patients 
with new CNCP diagnosis and 0.07 decrease for patients who did not have new CNCP 
diagnosis (Pr>t=0.00). In addition, the study also checked the count difference of yearly 
ED visits before and after the initiation of new opioid episode. There was 0.28 increase 
for patients started new long-term opioid treatment and 0.02 decrease for patients did not 
have long-term opioid treatment (Pr>t=0.00). 
 
5.2 Strengths and Limitations 
One of the strengths of this study is the cross-validation of findings from 
different data sources. The MEPS data contains national sample survey of families and 
their medical providers across the United States, which is a very complete data source 
for the cost and utilization of the healthcare services. The MEPS has rich data 
components to capture the demographic factors, SES characterizes, chronic disease 
conditions and health behaviors for the risk adjustment. The MEPS also includes both 
medical and pharmacy claims data to reflect the detailed services breakdowns. The 
MEPS sample includes people with either private or public insurance. Also, the MEPS 
 93 
 
panel data structure enables the longitudinal analysis cross different years to generate 
robust estimation of the causal relationship. On the other hand, the BCBSTX claims 
dataset is a regional private insurer’s administrative data, which offsets the reporting bias 
of self-reported MEPS data. The BCBSTX claims dataset covers 1/3 of the commercial 
insurance in Texas, which contains all medical and pharmacy claims for both 
professional and facility claims for BCBSTX members living in Texas under 65 years 
old. By using five years BCBSTX record, this study is able to track the change of health 
conditions and medical services utilization over time.   
Another strength of this study is adopting both cross-sectional and longitudinal 
models to test the hypothesis of correlation ship between increase of health expenditure 
and long-term opioid treatment for CNCP patients. The cross-sectional model compared 
total annual health expenditures for long-term opioid treatment CNCP patients and non-
long-term opioid treatment CNCP patients with same characteristics after PS-match and 
adjusted for all the potential cofounders. The longitudinal model checked the difference 
of total annual health expenditures for the same individuals before and after the new 
diagnosis of CNCP condition or initiation of new opioid treatment for CNCP patients, 
which excluded the difference for many characteristics at individual level since the 
comparisons were for the same patients pre- and post- initiation of new opioid treatment 
episode or diagnosis of new CNCP conditions. The longitudinal outcomes reveled the 
real relationship between opioid treatment and the change of health expenditures. 
Additional strength of the study is that the outcome variable of this study 
incorporated both health expenditure in dollar value and the counts of adverse event. The 
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money value can be used directly to estimate the national level healthcare opportunity 
cost for long-term opioid treatment. The comparison of adverse event (ER visits) count 
for treatment and control groups can provide more insight about where those higher cost 
comes from for the opioid group, and the scale of the difference for various health 
utilization buckets. That information is useful for improvement of opioid treatment or 
CNCP management by reducing the high cost adverse events. 
In Oct 2018, the Senate approved Dubbed the Support for Patients and 
Communities Act to address the opioid epidemic, following the House’s approval. The 
legislation is considered as a big breakthrough that will enhance access to addiction 
treatment and boost many interventions to impede the current opioid epidemic. The 
interventions cover law enforcement efforts against opioid abuse and combating the 
illegal opioid prescription.  Even though, the legislation aims to make addiction 
treatment more accessible, to reduce the illicit synthetic opioid, and to encourage non-
opioid pain treatment, the bill does not expand payment for addiction treatment and 
would not provide significant increase in spending for the opioid crisis. Considering the 
limited funding environment, the outcomes of this study provided decision makers an 
estimation about the direct cost and the potential savings for long-term opioid 
treatments. They can use that information to optimize the spending in different measures 
to combat the opioid crisis.  
Last, this study also appraised new incidences of CNCP condition and of the 
long-term opioid treatment, which could be populated to assess the national or regional 
health expenditure associated with the conditions and the treatment.  
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Several limitations should be noted. First, due to the constraint of the data, it was 
difficult to distinguish the opioid abuse and the regular opioid treatment. Thus, the 
results were impossible to distinguish the impact of normal opioid treatment and the 
opioid addiction/ abuse. As well, the comparison of health expenditures between opioid 
treatment and non-opioid treatment groups was among CNCP patients, which did not 
cover the opioid abuse patients without the CNCP conditions. Since this work mainly 
focused on the impact of regular long-term opioid treatment on CNCP patients not the 
impact of opioid abuse, this should not have biased the findings. 
Second, I did not adjust for all the potential confounders for the causal 
relationship between the opioid/CNCP and total medical expenditure, because the 
BCBSTX data set files do not include enough detail to implement the exact same risk 
adjustment as the MEPS data. Using risk adjustment would not affect underlying health 
expenditure, but it would lead to the more variability in the expenditure comparison.  
Third, this study only used the private insurance claim date to validate the self-
reported health utilization date. There might be some selection bias or geographic 
difference for the private claim sample and the MEPS sample. Also, the Medicare and 
Medicaid claims data were not included in the analysis, which might make the 
comparison more complete.  In the future, it will enhance our results if we could add 
public insurance claim data to the analysis. 
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5.3 Conclusion 
Chronic pain is one of the most prevalent reasons for doctor visits. In the national 
opioid crisis, it would be informative to not only understand the effectiveness of the 
opioid treatment, but also the potential cost of treatment. It is critical to investigate the 
health expenditure difference for opioid treatment when there has been lack of evidence 
to prove the long-term opioid treatments for CNCP as the best practice. By using 2011 
Medical Expenditure Panel Survey data and 2008-2012 Texas Blue Cross Blue Shield 
claim data. This study showed higher summed medical expenditures for CNCP patients. 
Moreover, this work proved long-term non-cancer pain could lead to economic, societal 
and health impacts. The opioid treatment for chronic non-cancer pain is related to higher 
medical spending and more emergency department visits. In the national fight against 
the opioid epidemic, it is critical to know the economic impact of long-term opioid 
treatment. This study not only proved the high medical spending of CNCP conditions, 
but it also underscores the increase of cost to the health care system for the long-term 
opioid treatment. And highlight the need for cost-effective pain treatments. 
Although there are some limitations of this analysis, the outcomes gave policy 
makers, payers, physicians, and CNCP patients insights about potential expenditure 
difference with and without the opioid treatment. Different from other studies focused on 
certain types of chronic pain, this estimation was for all types of CNCP by using both 
ICD diagnosis code and SF-12 Questionnaire. Policy makers could use this estimation to 
assess the social cost for the opioid treatment and accordingly make change of the opioid 
management. Payers could use this outcome to adjust the reimbursement. Physicians 
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could share this information with patients to help patient deciding on an appropriate 
CNCP management strategy.    
Although there are some limitations of this analysis, the outcomes give 
policymakers, payers, physicians, and CNCP patients insights about potential 
expenditure difference with and without the opioid treatment. Different from other one 
data sources study, this study analyzed both private insurance claims data and national 
survey data, which enhanced the validity and reliability of the outcomes. 
As one of the health economists, our main responsibility is to optimize the health 
care resources allocation in an effectively and efficiently way, under the limitation of 
funding, staff and facilities. The finding of this study showed quantified evidence of the 
impact for long-term opioid treatment. It gave solid proof of higher health expenditure 
and utilizations for opioid for CNCP patients. It could be used for comparison of 
different CNCP treatment approaches, by contributing cost information for incremental 
cost-effusiveness ratio.  
Policymakers could use this estimation to assess the social cost for the opioid 
treatment and accordingly make change of the opioid management. Payers could use this 
outcome to adjust the reimbursement. Physicians could share this information with 
patients to help patient deciding on an appropriate CNCP management strategy.  My 
results underscore the high cost of opioid treatment to the health care system and 
highlight the need for cost-effective CNCP treatments. 
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